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Abstract 
The scientific community has witnessed an exponential increase in the applications of 
graphene and graphene-based materials in a wide range of fields, from engineering to 
electronics to biotechnologies and biomedical applications. For what concerns 
neuroscience, the interest raised by these materials is two-fold. On one side, nanosheets 
made of graphene or graphene derivatives (graphene oxide, or its reduced form) can be 
used as carriers for drug delivery. Here, an important aspect is to evaluate their toxicity, 
which strongly depends on flake composition, chemical functionalization and dimensions. 
On the other side, graphene can be exploited as a substrate for tissue engineering. In this 
case, conductivity is probably the most relevant amongst the various properties of the 
different graphene materials, as it may allow to instruct and interrogate neural networks, as 
well as to drive neural growth and differentiation, which holds a great potential in 
regenerative medicine. In this review, we try to give a comprehensive view of the 
accomplishments and new challenges of the field, as well as which in our view are the most 
exciting directions to take in the immediate future. These include the need to engineer 
multifunctional nanoparticles able to cross the blood-brain-barrier to reach neural cells, and 
to achieve on-demand delivery of specific drugs. We describe the state-of-the-art in the use 
of graphene materials to engineer three-dimensional scaffolds to drive neuronal growth and 
regeneration in vivo, and the possibility of using graphene as a component of hybrid 
composites/multi-layer organic electronics devices. Last but not least, we address the need 
of an accurate theoretical modeling of the interface between graphene and biological 
material, by modeling the interaction of graphene with proteins and cell membranes at the 
nanoscale, and describing the physical mechanism(s) of charge transfer by which the 
various graphene materials can influence the excitability and physiology of neural cells. 
 
Keywords: graphene, neurology, brain, blood-brain barrier, nanomedicine, scaffolds, 
smart materials, computational modeling 
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1. Introduction 
Graphene (G) is a single- or few-layered sheet of Sp2-bonded carbon atoms tightly 
packed in a two-dimensional (2D) honeycomb lattice, with a thickness of only 0.34 nm 
(Geim, 2009). Each carbon atom has three µ-bonds and an out-of-plane π-bond that can 
bind with neighboring atoms (Geim, 2009), making G the thinnest compound ever known 
at one atom thick and the strongest compound discovered. Moreover, it is light, flexible 
and transparent and both electrically and thermally highly conductive, which opens the 
possibility of using it in a broad spectrum of applications, including supercapacitors (Sahoo 
et al., 2015;Casaluci et al., 2016) (Hess et al., 2011), flexible electronics (Eda et al., 
2008;Meric et al., 2008), printable inks (Zhu et al., 2015;Bonaccorso et al., 2016), batteries 
(Hassoun et al., 2014;Dufficy et al., 2015), optical and electrochemical sensors (Pumera, 
2009;Du et al., 2010;Kang et al., 2010), energy storage (El-Kady and Kaner, 
2013;Bonaccorso et al., 2015;Ambrosi and Pumera, 2016) and medicine (Novoselov et al., 
2012;Casaluci et al., 2016;Kostarelos et al., 2017;Reina et al., 2017). G-related materials 
(GRMs) include single- and few-layered G (1-10 layers; GR), G oxide (single layer, 1:1 
C/O ratio; GO), reduced G oxide (rGO), graphite nano- and micro-platelets (more than 10 
layers, but <100 nm thickness and average lateral size in the order of the nm and µm, 
respectively), G and G oxide quantum dots (GQDs and GOQDs, respectively), and a 
variety of hybridized G nanocomposites (Bianco, 2013;Wick et al., 2014;Cheng, 2016). 
Having such different composition and structures, these compounds possess very diverse 
properties that have to be taken in consideration when planning biomedical applications, 
as they elicit completely different biological responses. Thus, it is fundamental to properly 
identify and characterize the GRMs employed, to overcome the widespread lack of 
reproducibility affecting biological experiments with G materials. 
In the last few years, biomedical applications of G have attracted an ever-increasing 
interest, including the use of G and GRMs for bioelectrodes, bioimaging, 
drug/gene/peptide delivery, nanopore-based DNA-sequencing, stem cell differentiation 
and tissue engineering (Feng et al., 2013;Yang, 2013). Moreover, GRMs have generated 
great interests for the design of nanocarriers and nanoimaging tools, two- and three-
dimensional tissue scaffolds, anti-bacterial coatings and biosensors (Bitounis et al., 
2013;Ding et al., 2015). The interest in using GRMs in medicine lies chiefly upon the 
extraordinary properties of G, including its mechanical properties, flexibility, transparency, 
thermo-electrical conductivity and good biocompatibility. GRMs could therefore 
overcome the limitations of metals and silicon, which are currently used for implantable 
devices, but are characterized by elevated stiffness, high inflammatory potential and poor 
long-term stability in physiological environments. Moreover, the biomedical field 
witnesses a strong need for innovative therapies to assess the increasing demand of more 
specific, safer and effective treatments for pathological conditions. Given these premises, 
a large amount of research on G focuses on medical applications, and particularly in the 
field of neurology, where its mechanical and electronic features make it a strong candidate 
for replacing current devices (Kostarelos et al., 2017;Reina et al., 2017).  
Another appealing aspect of GRM-based medical devices lies on the increasing 
evidences of G biocompatibility, an extreme important issue to take into consideration for 
any new biomaterial brought to the market. Due to its chemistry, G surface allows strong 
and non-destructive interactions at the cellular level, which could even be improved by 
specific chemical functionalization (Cheng, 2016;P. Kang, 2016). This is particularly true 
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for G-based supports and scaffolds oriented to tissue repair and regeneration, and in fact 
promising results have already been shown for neural and bone tissue engineering (Cheng, 
2016;Reina et al., 2017). For what concerns G nanosheet dispersions, mostly intended for 
drug/gene delivery and diagnostic imaging purposes, the scenario is instead more complex 
(Bramini et al., 2016;Mendonca et al., 2016a;Rauti et al., 2016). The safety of this material 
is indeed still a challenging problem to address and every case needs to be analyzed 
separately by taking into account the synthesis method, the quality of the final product 
including its purity and the eventual presence of trace contaminants, as well as the 
biological environment in which G is to be applied. 
 
Graphene applications in neuroscience. The biomedical applications of G represent a 
field in continuous expansion. Traditional treatments for central nervous system (CNS) 
disorders present a number of challenges, thus, developing new tools that outperform the 
state of the art technologies for imaging, drug delivery, neuronal regeneration and electrical 
recording and sensing is one of the main goal of modern medicine and neuroscience 
(Baldrighi et al., 2016). Since the development of carbon-related materials, 
nanotechnology has strongly impacted a number of applications (Figure 1) including: 
drug, gene and protein delivery, to cross the blood-brain barrier (BBB) and reach 
compromised brain areas; neuro-regenerative techniques to restore cell-cell 
communication upon damage by interfacing two (2D) or three (3D) dimensional scaffolds 
with neural cells; highly specific and reliable diagnostic tools, for in vivo sensing of disease 
biomarkers by cell labeling and real-time monitoring of biological active molecules; and 
neuronal activity monitoring and modulation, by highly sensitive electrodes for recordings 
and G-based platforms for electrical local stimulation (Mattei and Rehman, 2014;John et 
al., 2015;Chen, 2017;Kostarelos et al., 2017;Reina et al., 2017). 
In detail, researchers have already started exploring the use of G at the CNS for cell 
labeling and real-time live-cell monitoring (Wang et al., 2014;Zuccaro et al., 2015); 
delivery to the brain of molecules that are usually rejected by the BBB (Tonelli et al., 
2015;Dong et al., 2016); G-based scaffolds for cell culture (Li et al., 2013a;Menaa et al., 
2015;Defterali et al., 2016); and cell analysis based on G-electrodes (Medina-Sanchez et 
al., 2012;Li et al., 2015). In addition, interfacing G with neural cells was also proposed to 
be extremely advantageous for exploring their electrical behavior or facilitating neuronal 
regeneration by promoting controlled elongation of neuronal processes (Li et al., 2011;Tu 
et al., 2014;Fabbro et al., 2016). These applications open up new research lines in neuro-
therapeutics, including neuro-oncology, neuro-imaging, neuro-regeneration, functional 
neuro-surgery and peripheral nerve surgery (Mattei and Rehman, 2014). 
 
In this review we will focus on few aspects of GRM research that we deem of particular 
interest for future neuroscience applications, i.e. (i) G as nano-carrier for drug and gene 
delivery, (ii) G interaction with the blood-brain barrier (BBB), and (iii) G-based 2D and 
3D composites for neural regeneration, stimulation and recording. A final (iv) chapter is 
dedicated to an overview of computational modeling approaches that can help biologists 
and medical scientists to better understand the molecular and cellular interaction of G with 
living systems. 
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Figure 1. Graphene based neural interfaces for a variety of neuronal functionalities 
like recording, stimulation and biosensing. Modified with permission from Kostarelos 
et al. (Kostarelos et al., 2017). 
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2. How to reach the brain: G-based nanocarriers and the blood-brain barrier 
 
2.1. Graphene nanosheet interaction with neural cells 
Common mechanisms of cytotoxicity of G nanosheets have been reported in literature 
on different cell types, and include the physical interaction with cell membranes (Seabra et 
al., 2014); disruption of cell cytoskeleton (Tian et al., 2017); oxidative stress due to 
production of reactive oxygen species (ROS) (Chen et al., 2016;Mittal et al., 2016); 
mitochondrial damage (Pelin et al., 2017); DNA damage, such as chromosomal 
fragmentation, DNA strand breakages, point mutations, and oxidative DNA alterations 
(Fahmi et al., 2017); autophagy (Chen et al., 2014); and apoptosis and/or necrosis (Lim et 
al., 2016). Furthermore, published data suggest that GO is less toxic than G, rGO and 
hydrogenated-G; smaller nanosheets are less toxic than large flakes and highly dispersible 
G solutions are safer than aggregating ones (Donaldson et al., 2006;Bianco, 2013;Kurapati 
et al., 2016;Ou et al., 2016). 
In the case of the CNS, the mechanisms of interaction of GRMs with neurons and 
astrocytes are still poorly investigated and unclear, depicting an undefined scenario mainly 
dependent on GRM intrinsic characteristics. Specifically, no changes in neuronal and glial 
cell viability were detected upon G exposure, both in vivo and in vitro (Bramini et al., 
2016;Mendonca et al., 2016b;Rauti et al., 2016). However, primary neuronal cultures 
exposed to GO nanosheets displayed clear alterations in a number of physiological 
pathways, such as calcium and lipid homeostasis, synaptic connectivity and plasticity 
(Bramini et al., 2016;Rauti et al., 2016). Once internalized in cells, G nanosheets were seen 
to preferentially accumulate in lysosomes, as well as to physically damage mitochondria, 
endoplasmic reticulum and, in some cases, nuclei (John et al., 2015). Another study 
suggested that the irregular protrusions and sharp edges of the nanosheets could damage 
the plasma membrane, thus letting G entering the cell by piercing the phospholipid-bilayer 
(Li et al., 2013b). These features raise additional safety concerns, as free GRMs in the 
cytoplasm may lead to disruption of the cytoskeleton, impaired cell motility and blockade 
of the cell-cycle, similar to carbon nanotube-induced cytotoxicity. 
The above-described effects were observed upon chronic G exposure, stressing the 
need of urgent and further biocompatibility assessment of the material with nerve tissues 
in long-term studies, hopefully linking in vivo effects to in vitro cellular and molecular 
interactions. A first strong evidence of G-induced CNS toxicity came from a recent in vivo 
study (Ren et al., 2016). To recreate a situation of G environmental pollution, researchers 
dispersed GO in water in the presence of Danio rerio (zebrafish) larvae. Exposed larvae 
displayed GO in the CNS and, most importantly, an induction of Parkinson’s disease-like 
symptoms such as disturbance of locomotor activity, dopaminergic neurons loss and 
formation of Lewy bodies. These effects were likely a consequence of mitochondrial 
damage and apoptosis through the caspase 8 pathway, in the presence of a more general 
metabolic disturbance. G and GO nanosheets accumulate in small quantities in the CNS of 
rodents after intravenous (i.v.) injection without prior surface functionalization (Mendonca 
et al., 2016a;Mendonca et al., 2016b). rGO was also detected in brain tissues, particularly 
in the thalamus and hippocampus, after i.v. injection that was accompanied by blood-brain 
barrier (BBB) disruption (Mendonca et al., 2016b). Interestingly, rats treated with rGO 
flakes did not show any clinical signs of neurotoxicity, including no signs of tremor, 
convulsions, salivation, lacrimation, dyspnea and motor abnormalities. These findings are 
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in contrast with the work carry out by Zhang et al. (Zhang et al., 2015), who reported the 
short-term decrease in locomotor activity and neuromuscular coordination in mice orally 
administered with rGO nanosheets. This discrepancy underlines that the route of 
administration is key parameter in determining G biocompatibility. Thus, the portal of entry 
of G into the organism, together with its dose, size, functionalization and aggregation, will 
determine the final biological effects. 
 
In summary, the current data on G nanosheet biocompatibility are still controversial. 
This is due to the high heterogeneity of materials present on the market and the large variety 
of synthesis methods. Depending on the graphite source (starting material), the synthesis 
method, the use of chemicals and the dispersion form (solution or powder) of the final 
product, G can present different sizes, thickness, chemical surface and aggregation state, 
which all affect to various extent its interaction with the biological systems. It is clear, 
however, that G nanosheets may cause adverse environmental and health effects, leaving 
open the debate about their use as biomedical platform (Bramini et al., 2016;Reina et al., 
2017). To date, GO nanosheets are preferred with respect to pristine G for biomedical 
studies, because of their major solubility and stability in biological fluids (Chowdhury et 
al., 2013;Servant et al., 2014a;Reina et al., 2017).  
 
2.2. Graphene for biomolecule delivery to the central nervous system 
As discussed above, the use of G nanosheet dispersions for biomedical applications 
could give some unwanted effects due to the intrinsic characteristics of the material. 
Interestingly, functionalizing the G surface could alleviate most of these drawbacks. The 
physical-chemical properties of G nanosheets can be tuned toward a higher degree of 
biocompatibility. Moreover, cargoes can be loaded via π-π stacking interactions, hydrogen 
bonding, or hydrophobic interactions (Georgakilas et al., 2016) giving the attractive 
possibility of using G as a platform for delivery of biomolecules that are usually rejected 
by the BBB. In fact, the large surface area available and the possibility of conjugating 
different molecules onto its surface, make G a suitable material for holding and carrying 
drugs, genes (including siRNA and miRNA), antibodies and proteins (Chen et al., 2013). 
In addition, it is also possible to modify its chemical structure by adding functional groups 
such as amino, carboxyl, hydroxyl, alkyl halogen, or azide groups (John et al., 2015). 
Surface functionalization has the double advantage of loading high quantity of 
biomolecules and specifically deliver them to target cells, while allowing a more 
homogenous dispersion of the material, since pure G is highly hydrophobic and tends to 
aggregate in aqueous solution, including biological fluids containing salts and proteins 
(Mattei and Rehman, 2014;John et al., 2015). Additionally, functionalized G nanosheets 
could be applied in systemic, targeted, and local delivery systems (Feng et al., 2011;Kim 
et al., 2011;Liu et al., 2013b). Thus, this approach could fulfill the increasing demand of 
multifunctional and versatile medical platforms. 
Because of its unique fluorescent, photoacustic and magnetic resonance profiles, 
several studies have also explored the possibility of incorporating G-based nanoparticles 
to enhance the in vivo visualization of brain tumors and improve tumor targeting of 
molecular anticancer strategies (Kim et al., 2011;Yang et al., 2012;Zhang, 2013;Hsieh et 
al., 2016). Also in this case, in vivo studies revealed that GO, more than GR, has good 
potential for these applications, in fact, systemically administered radiolabeled GO (188Re-
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GO) could reach the brain parenchyma, although in a small amount (0.04%) (X. Zhang, 
2011). 
 
2.3 Blood-brain barrier crossing 
The blood-brain barrier (BBB) is one of the most important physiological barriers in the 
organism, forming a dynamic interface that separates the brain from the circulatory system 
(Pardridge, 2001;Begley, 2004). The barrier is formed by cerebrovascular endothelial cells, 
surrounded by basal lamina and astrocyte perivascular endfeet that link the barrier system 
to the neurons (Abbott et al., 2010). Together with pericytes and microglial cells, 
endothelial cells support the barrier function and regulate its intercellular signaling to 
control the flow and trafficking to the brain (Dohgu et al., 2005;Abbott et al., 2010). The 
BBB, together with arachnoid and choroid plexus epithelium, restricts the passage of 
various chemical substance and foreign materials between the bloodstream and the 
neuronal tissue, while still allowing the passage of substances and nutrients essential to 
metabolic functions, from oxygen to various proteins, such as insulin and apolipoprotein E 
(Abbott et al., 2006;Strazielle and Ghersi-Egea, 2013). An interesting point is that the brain 
capillary endothelial cells clearly differ from the endothelial cells in the other districts of 
the body, in that they present a larger number of adherens and tight junctions between 
adjacent cells, so that no inter-cellular fenestrations exist (Abbott et al., 2006;Abbott et al., 
2010). The tight junctions between the brain capillary endothelial cells are one of the most 
important structural and anatomical elements of the BBB. They create the major barrier, 
associating cell membranes tightly together and regulating paracellular movements of 
water, molecules, ions and other biomolecules (Begley and Brightman, 2003;Abbott et al., 
2010). Based upon these characteristics, some researchers have highlighted that the 
permeability properties of the BBB reflect the tightness of intercellular junctions between 
brain capillary endothelial cells (Rubin et al., 1991). In other words, the low permeability 
characterising the BBB is caused for the most part by tight and adherens junctions that limit 
paracellular passage (Wolburg and Lippoldt, 2002). The result is that most molecular traffic 
is forced to take a transcellular route across the BBB, rather than moving paracellularly 
through the junctions, as in most endothelia (Abbott and Romero, 1996;Wolburg and 
Lippoldt, 2002;Hawkins et al., 2006). 
To date, several mechanisms of transport across the BBB have been identified (Figure 
2), including paracellular or transcellular pathways, transport proteins (carriers), receptor-
mediated transcytosis and adsorptive transcytosis (Abbott et al., 2006). Transcytosis is a 
process whereby biomolecules are engulfed into a plasma membrane invagination and 
further transported from one side of the polarized cell monolayer to the other side. Specific 
proteins, such as insulin and transferrin, are taken up by receptor-mediated endocytosis and 
transcytosis, a process known as receptor-mediated transport (Kreuter et al., 2002;Rip et 
al., 2009;Ulbrich et al., 2009;Ulbrich et al., 2011). Native plasma proteins, such as albumin, 
are poorly transported, but cationisation can increase their uptake by adsorptive-mediated 
endocytosis and transcytosis (Abbott and Romero, 1996;Pardridge, 2007a). In addition to 
transcytosis, very small water-soluble compounds can penetrate the tight junctions through 
a paracellular aqueous pathway. In paracellular transport, tight junctions act as a 
“gatekeeper” and regulate paracellular diffusion of water-soluble agents. For example, 
sucrose is a water-soluble molecule and is able to cross the BBB in limited amounts by 
paracellular diffusion (Ek et al., 2006). The large lipid membrane surface area of the 
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endothelium also offers an effective diffusive route (transcellular transport) for small 
gaseous molecules such as O2 and lipid-soluble agents, including drugs such as barbiturates 
and ethanol. The endothelium furthermore contains transport proteins for glucose, amino 
acids, purine bases, nucleosides, choline and other substances. Some transporters, i.e. the 
P-glycoprotein, are energy-dependent and act as efflux transporters (active-efflux 
transport).  
The complex network of transport systems described above, gives the BBB a vital 
neuroprotective function that however comes with some drawbacks, as the BBB also 
impedes the passage of drugs for CNS diseases. Pharmaceutical companies have invested 
significant effort and sums in trying to design drugs that can cross the BBB, with very 
limited success. It is reported that only 5% of the total amount of drugs developed for 
neuronal diseases actually reach the CNS (Pardridge, 2007b).  
 
 
 
Figure 2. Pathways across the blood-brain barrier. Modified with permission from 
Abbott et al. (Abbott et al., 2006) 
 
2.4 Nanoparticle engineering 
The therapeutic potential of nanoparticles (NP) exposure depends chiefly on the rate of 
NP penetration when delivered from the external environment to the internal bio-
compartments. Thus, biological barriers are central in determining the biological impact of 
NP exposure. Nanomaterials offer enormous potential for therapeutics and diagnosis, but 
also raise the possibility of unintended access to the brain (Herda, 2014). In vivo studies 
showed that nanoparticles could be found in the CNS upon various ways of administration 
(Semmler-Behnke et al., 2008;Zensi et al., 2009;Zensi et al., 2010). In parallel, in vitro 
models of human and murine BBB have been used and developed for the investigation of 
NP translocation (Andrieux and Couvreur, 2009;Ragnaill et al., 2011;Bramini et al., 
2014;Herda, 2014;Raghnaill et al., 2014).  
Numerous nano-delivery systems have been proposed and tested for therapeutic 
purposes, both in vitro and in vivo (Pandey et al., 2016). Amongst the state-of-the-art 
	 10	
systems, polymeric NPs are promising because of their high drug encapsulation capacity, 
so they protect and transport hydrophobic drugs without damaging the BBB structure (Tosi 
et al., 2008). Binding apolipoprotein E to NPs has been suggested as a mechanism via 
which NPs could utilize existing pathways to access the brain (Kreuter et al., 2002;Wagner 
et al., 2012), and it indeed enhances the uptake of drugs (Michaelis et al., 2006). This 
approach is particularly promising with liposomes, which are highly biocompatible (Re et 
al., 2011). In general, exploiting receptor-mediated transcytosis by linking specific 
peptides to the NP surface has been the most studied system in the field of BBB crossing. 
Various molecules, such as transferrin, insulin, lectin and lipoproteins, physiologically use 
this route to pass from the blood stream to the brain; thus these ligands could increase the 
passage ratio of drug-loaded NPs through the BBB for therapeutic purposes (Herda, 
2014;Åberg, 2016;Pandey et al., 2016). Recently, exogenous peptides known to undergo 
transcytosis in the BBB were also grafted to the NP surface to enhance their entrance in 
the CNS. Here, particular attention has been given to the diphtheria toxin receptor (DTR) 
and the HIV-TAT proteins. A mutant of DTR with no toxicity or immunogenicity has been 
tested to transport nano-liposomes and polybutylcyanoacrylate NPs across the BBB, both 
in vitro and in vivo, and indeed, only grafted NPs were able to transcytose the barrier (van 
Rooy et al., 2011;Kuo and Chung, 2012;Kuo and Liu, 2014). The same strategy was 
successful when using a derivate of the HIV-TAT protein, linked to the surface of 
polymeric micelles or SiO2 NPs through PEG molecules (Liu et al., 2008a;Liu et al., 
2008b;Zhao et al., 2016a). In addition, antibody-grafted NPs have been synthetized to 
specifically target brain vascular endothelium receptors (Loureiro et al., 2014;Saraiva et 
al., 2016), in order to exploit the physiological transcytosis mechanisms of the BBB. Once 
again, the most promising results were obtained with antibodies anti-Insulin (Ulbrich et al., 
2011), anti-transferrin (Clark and Davis, 2015) and anti-LDL (Kreuter, 2014) receptors. 
Even though these recent developments in antibody engineering have improved the 
knowledge on brain therapeutics, by increasing targeting specificity and avoiding 
peripheral loss of the material, still significant efforts have to be made to translate these 
findings from research to clinical applications. 
A major challenge of spherical NPs is that it is difficult to obtain a multifactorial 
engineered system able to encapsulate a drug, cross the BBB by receptor-mediated 
endocytosis and finally target a specific cellular subpopulation. In fact, even though NPs 
present a high surface area, the room for engineering peptides and molecules on the surface 
to drive and guide the system towards various body compartments is still limited. In this 
scenario, new approaches that combine external modulation of BBB permeability with NP 
engineering have been recently developed and are currently under investigation. 
 
2.5 Surfactants coverage and hyperthermia 
A very similar approach to the above-described NP surface modification with ligands 
consists in covering NPs with surfactants (Pardridge, 2012). This strategy induces a 
transient disruption of tight junctions, leading to higher permeability of the endothelium, 
thus allowing large molecule and nano-carriers to easily cross the BBB and reach the brain 
(Pardridge, 2012;Saraiva et al., 2016). Moreover, poly(sorbate 80) can adsorb 
apolipoprotein E and/or A-I, additionally giving NPs the capacity of binding lipoprotein 
receptors expressed in the brain endothelium and crossing the BBB (Kreuter et al., 
2003;Petri et al., 2007). 
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In the last few years, researches have adopted innovative strategies with the aim of 
reduce BBB damage and increase the amount of drug transported to the CNS. One stream 
of research aimed at obtaining the time- and area-specific upregulation of BBB 
permeability, to facilitate NP passage. This was achieved, for example, by activating the 
A2A adenosine receptor, which increases the intercellular space between the brain capillary 
endothelium (Gao et al., 2014). A similar effect can be obtained by physically interacting 
with the BBB by inducing hyperthermia, a procedure that increases the local temperature 
of the endothelium to 41-43 °C. The change in temperature acts by selectively disrupting 
tight junctions and increases the paracellular permeability of the BBB. Interesting results 
were obtained using focused ultrasounds (FUS) and microbubbles, which showed very low 
tissue toxicity and high accumulation of doxorubicin in the CNS (Treat et al., 2007). Other 
techniques to produce hyperthermia are microwaves and radiofrequency. The latter has 
been tested in vivo for glioma treatment, in combination with classical chemotherapy and 
radiotherapy, displaying encouraging results (Wang et al., 2012). Finally, two more 
advanced strategies to induce hyperthermia have been recently tested: laser pulse and 
magnetic heating. Near-infrared ultrashort laser pulses induced BBB disruption in selected 
regions, thus allowing the passage of large molecules in the brain (Choi et al., 2011). 
Magnetic NPs (MNPs) were instead used for delivering bioactive compounds via heat 
generated from magnetic heating, using a low radiofrequency field (Tabatabaei et al., 
2015). Since MNP location can also be monitored live, this technique can be applied for 
both treatment and diagnosis of diseases. 
Despite the promising results, techniques that modulate and interfere with the BBB 
permeability, even if transiently and locally, are burdened by a major problem, i.e. that 
there is very poor control over the passage of unwanted molecules and/or microorganisms 
that populate the blood stream. If it is true that the amount of drug reaching the brain is 
increased upon tight junction opening, it is also true that toxic compounds, safely 
constrained to blood vessels by an intact BBB, may pass at the same time, posing high risks 
to the patient.  
 
2.6 Graphene and the BBB: a new way for drug & gene delivery to the brain. 
The key goal of any drug delivery system is to create a smart tool that recognizes 
specific targets and releases the drug in a controlled way (Allen and Cullis, 2004). The 
main limitation of G-based applications in neuroscience is its very low accumulation in the 
brain parenchyma upon intravenous injection. Once injected intravenously, G will engage 
with ions, lipids and proteins, resulting in the aggregation of the material and formation of 
a biomolecular corona that might affect the distribution of G and trigger inflammatory 
responses (Dell'Orco et al., 2010). In addition, nanosheets can be phagocytosed by 
macrophages, inducing activation and release of pro-inflammatory cytokines (Zhou et al., 
2012), and interact with several blood components inducing hemolysis (Liao et al., 2011). 
Last but not least, G nanosheets could accumulate in the reticulo-endothelial system rather 
than in the tissue to which they are targeted (McCallion et al., 2016). 
Particularly challenging is the passage through the BBB, which significantly limits the 
delivery of drugs, blocking roughly the 100% of large molecule neuro-therapeutics and 
more than 98% of all small-molecule drugs (Upadhyay, 2014). Accordingly to Mendonca 
et al., systemically injected rGO nanosheets cross the BBB through a transitory decrease 
in the BBB paracellular tightness and accumulate in the thalamus and hippocampus of rats 
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(Mendonca et al., 2016b). On the contrary, functionalization of rGO with polyethylene 
glycol (PEG), usually used to improve biocompatibility of nanomaterials, induces BBB 
breakdown and astrocyte dysfunctions in vivo (Mendonca et al., 2016a). Among the various 
approaches to make G cross the BBB, ultrasounds were applied to mice to physically open 
BBB tight junctions and allow the drug delivery system to enter the brain. By following 
this method, GO nanosheets grafted with Gd-DTPA and poly(amidoamine) dendrimer, and 
loaded with EPI and the tumor suppressor miRNA Let-7, could reach the brain upon tail 
vein injection (Yang et al., 2014). The main advantage of this approach is the reversibility 
of the BBB opening. Interestingly, G allowed at the same time high contrast MRI analysis 
and a quantification of the distribution of the delivery system inside the brain tissue (Yang 
et al., 2014). These results are promising, however in-depth pharmacokinetics and 
toxicological studies are needed, especially for long-term treatments, keeping in mind that, 
with respect to what has been studied so far, this technique achieves a much higher G 
accumulation in the CNS. 
Alternatively, G surface can be functionalized with specific biomolecules that enable 
the material to cross the BBB (Allen and Cullis, 2004;Goenka et al., 2014;John et al., 
2015). A recent study has investigated an innovative nano-delivery system with high 
loading capacity and a pH dependent behavior. The GO@Fe3O4 nanocomposite was 
conjugated to lactoferrin (Lf), an iron transporting serum glycoprotein that binds to 
receptors overexpressed at the surface of vascular endothelial cells of the BBB and of 
glioma cells, in order to obtain Lf@GO@Fe3O4. After loading the NPs with doxorubicin 
(DOX), a drug used to treat glioma (Figure 3), NPs were intravenously injected and the 
particles were seen to migrate from the bloodstream to glioma cells (Liu et al., 2013a). NPs 
were more concentrated in the CNS compared to other organs, and a higher efficiency in 
tumor regression was observed, compared to the control of animals injected with DOX 
alone. Following a similar approach and with similar promising results, Yang et al. 
functionalized PEG-GO nanosheets with the Tat protein of the Human Immunodeficiency 
Virus (HIV), which allowed the drug-loaded PEG-GO system to cross the BBB by 
transcytosis, while leaving the barrier endothelium fully preserved (Yang et al., 2015a). 
As previously discussed, another promising strategy to challenge the BBB is NP 
coating with surfactants (Kreuter et al., 2003;Gelperina et al., 2010). Kanakia et al. 
(Kanakia et al., 2014) improved GO delivery to the CNS by functionalizing the nanosheets 
with dextran; the material was found to cross the BBB and reach the brain without exerting 
toxic effects. Surprisingly, the GO concentration in the CNS increased with time, while 
remaining almost absent in other organs. Thus, the study suggests a slow accumulation of 
G in the CNS and long-term persistency of the material, that is encouraging from the point 
of view of the drug delivery system, but also raises safety concern on long-term toxicity of 
G nanosheets (Baldrighi et al., 2016), an issue that still needs to be assessed. 
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Figure 3. Transferrin modified GO for glioma-targeted drug delivery. Modified with 
permission from Liu et al. (Liu et al., 2013a) 
 
The number of drugs successfully linked to G nanosheets is increasing. Liu and 
colleagues (Liu et al., 2008c) showed that GO-PEG flakes could be decorated with the 
water insoluble aromatic molecule 7-ethyl-10-hydroxy-camptothecin (SN38), via non-
covalent van der Waals interactions. Similarly, other drugs, including different 
camptothecin analogues (Liu et al., 2008c), Iressa (gefitinib) (Liu et al., 2008c), and DOX 
(Sun et al., 2008), were successfully attached onto the GO-PEG complex by simple non-
covalent binding. rGO-PEG particles were able to cross the endothelial layer of the BBB 
without disrupting the tight junctions, in both in vitro and in vivo studies (Mendonca et al., 
2016a;Mendonca et al., 2016b). Recently, Xiao et al. used GQDs conjugated to a neuro-
protective peptide. Once injected intravenously in a murine model of Alzheimer disease, 
they were able to increase learning and memory, dendritic spines formation and decrease 
pro-inflammatory cytokine levels (Xiao et al., 2016). 
One of the main applications of G-based drug delivery systems is anticancer therapy, 
by linking G composites with chemotherapeutics. Given their strong optical absorbance in 
the near-infrared (NIR) region, G-based hybrid materials are also intensively studied for 
their promising applications in cancer phototherapy (Liu, 2011;Honigsmann, 2013) 
(Robinson et al., 2011;Yang et al., 2012). The rationale beyond this approach is to exploit 
the heat produced by the G accumulated in tumor regions upon NIR laser stimulation to 
kill cancer cells. This technique was successfully applied in vitro using U251 glioma cells 
(Markovic et al., 2011). Such experimental approaches are of special interest, as they might 
help overcoming the limitations imposed by the BBB (Abbott, 2013), and are very 
promising especially for the treatment of very resistant and aggressive tumors, such as the 
glioblastoma. 
The intrinsic properties of G in the visible (VIS) and NIR range make it also an 
attractive tool for bio-imaging (Zhang, 2013) both in vitro and in vivo (Gollavelli and Ling, 
2012). For example, aptamer-carboxyfluorescein/GO complexes were employed for 
intracellular monitoring and in situ molecular probing of specific clusters of living cells, 
such as artificially implanted tumors in mice. GO nanosheets were also used for photo-
acoustic imaging, which relies on the acoustic response on heat expansion following optical 
energy absorption (Wang et al., 2010;Yang et al., 2010;Qian et al., 2012). Specifically for 
CNS applications, in vivo studies showed that intracranial administered PEG-GO and its 
derivatives can be imaged in the brain by two-photon microscopy (Qian et al., 2012). 
Through this imaging technique, a 3D distribution map can be reconstructed in the brain 
parenchyma due to the high tissue penetration of the fluorescence signal of PEG-GO 
composites. These promising results could lead to the use of G as a diagnostic tool for 
imaging brain cancerous lesions, especially if the material is engineered with biomolecules 
that specifically target tumorigenic cells. Furthermore, once the targeting is achieved, G 
properties can be optimized according to the specific application, i.e. the size and oxidation 
state might be changed to shift the emission wavelength from VIS to NIR, which has a 
deeper tissue penetration, thus improving the depth of the diagnostic imaging device. By 
combining the optical properties of G with other biodegradable and functional materials, it 
will be possible to create G-based composites and hybrids suitable for several live-imaging 
applications. So far, most of the tools have been tested in vitro on cancer cell lines, and in 
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vivo for cancer detection and diagnosis, leaving unaddressed the possibility of using them 
to explore and image the CNS (Zhang, 2013;Cheng, 2016). 
Similarly to drug delivery, also genetic engineering can exploit G properties and open 
new opportunities in biomedicine. The concept in this case would be to deliver nucleic 
acids, i.e. DNA or various types of RNA molecules, including miRNA and shRNA, to 
specific target cell populations, to restore physiological conditions (Cheng, 2016). The 
development of non-viral systems is of great importance for future medical approaches as 
G could allow overcoming some of the intrinsic limitations of viral systems, such as 
difficulties in accommodating long nucleic acids, batch-to-batch variations, elevated costs 
and the immunogenicity of viral vector systems (Kim et al., 2011;John et al., 2015). 
Different strategies have been developed, including the decoration with positively charged 
polymers (PEI, BPEI), dendrimers (PAMAM) and polysaccharides, which enhance gene 
transfection efficiency by promoting the interaction with the cell membrane (Liu et al., 
2014;Paul et al., 2014). Being the technique of functionalization the same, both drugs and 
genes can be delivered simultaneously using G-based hybrid materials (Zhang et al., 2011). 
This would exhibit a synergic effect, as it would bring a significant enhancement of drug 
as well as transfection efficiency. On this line, G-nanosheets were functionalized with the 
cationic polymer PEI, a non-viral gene vector that forms strong electrostatic interactions 
with the negatively charged phosphate groups of both RNA and DNA (Feng et al., 2011). 
A step further was taken by Chen et al., that used PEI-functionalized GO for gene delivery 
yielding a high transfection efficiency in the absence of any cytotoxic effect (Chen, 2011).  
In summary, G-based delivery systems, when conveniently functionalized or associated 
with complementary technologies, represent promising candidates for both diagnostics (i.e. 
imaging) and therapeutics (i.e. drug and gene delivery) neuroscience applications. 
Moreover, in spite of few studies showing toxic effects of exposure the nervous system to 
bare G and rGO (Bramini et al., 2016;Mendonca et al., 2016b;Rauti et al., 2016), to date 
there is no solid evidence that functionalized-G is harmful to neuronal cells and the BBB. 
Since G-based technologies for biomedical applications are constantly and rapidly 
evolving, the near future may see the development of new safe and highly neurocompatible 
materials. 
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3 Graphene substrates as neuronal interfaces 
Tissue engineering aims to restore the functionality of a disrupted tissue by interfacing 
it with suitable biomaterials. This is a fast-expanding field of research in need of innovative 
approaches to achieve highly biocompatibile, functional and low invasive implants for 
long-term applications. For what concerns the nervous system, active and dynamic 
implantable devices are extremely advantageous as they allow to simultaneously stimulate 
and record electrical activity of neural cells. Various types of implantable devices have 
been developed to be used as neural interfaces. Amongst these are deep brain stimulations 
implants (DBI) for the electrical stimulation of deep structures in the CNS, clinically used 
to treat dystonia and tremor in Parkinson’s disease (Perlmutter and Mink, 2006), retinal 
and cochlear implants to electrically stimulate the surviving neurons in the presence of 
retinal degeneration or to convert external sounds in electrical impulses (Spelman, 
2006;Picaud and Sahel, 2014), central and peripheral nervous system stimulators for motor 
rehabilitation after spinal cord lesions (Hatsopoulos and Donoghue, 2009), and intracranial 
electrodes to map brain electrical activity for diagnostic purposes (Chang, 2015).  
The intrinsic properties of G can be exploited to design G-based devices for neuronal 
interfaces, as G can enhance the optical, electrical and mechanical properties of composite 
nanostructures. In general, fundamental requirements for a good neural implant are a good 
biocompatibility coupled to minimal inflammatory response, adequate signal-to-noise ratio 
if neural recordings are envisaged, and minimal invasiveness, preserving the integrity of 
the implanted tissue. Typically, G-based scaffolds can be classified according to their 
dimensionality, i.e. one-dimensional (fibers, ribbons or yarns), two-dimensional (papers, 
films) and three-dimensional (Cheng, 2016;Reina et al., 2017). The most common 
applications of G-based structures in nanomedicine include the engineering of scaffolds for 
in vivo neuronal regeneration, stimulation and recording, and for on-demand drug delivery 
(Cong et al., 2014;Cheng, 2016). For what concerns in vivo applications, the use of 2D 
devices is mostly limited to planar electrodes (Liu et al., 2016;Park et al., 2018). In fact, 
several G-based 2D devices have been engineered, but due to technical limitations, so far 
they have been tested mainly in vitro (for a comprehensive review of 2D, G-based 
substrates applied to neuronal cells see book chapter Bramini et al. (in press) (Bramini, 
2018). For example, in the case of CVD-G, the limiting step is the transfer of the monolayer 
G onto the final substrate, a process that often creates contaminants and defects in the G 
structure. In addition, a suitable substrate that will interfere as less as possible with the 
chemical-physical characteristics of G is still to be found. Furthermore, 2D devices were 
less active in vitro with neuronal stem cells compared to 3D scaffolds with the same surface 
chemistry (Jiang et al., 2016), clearly indicating that morphology, dimensionality, 
accessibility and porosity are critical scaffold features. Indeed, foams and hydrogels are the 
scaffolds of choice to drive regeneration in the brain, while directional conduits are 
preferred to drive re-growth of peripheral nerves. In the next paragraph we will discuss the 
latest developments in the use of 3D G-based scaffold in neuroscience, focusing on the link 
between the G content and structure of the device, and its functionality. 
  
	 16	
3.1 3D G-based scaffolds: composites, foams, fibers and hydrogels. 
Applications of G-based materials in the neurology field will only be possible upon 
development of three-dimensional scaffolds able to support nerve regeneration across the 
injured/lesioned site. The unique properties of planar 2D G-scaffolds are exceeded by 3D 
G-structures, which provide a microenvironment where cells are able to grow under 
conditions that are closer to the in vivo situation. In addition, as previously mentioned, 3D 
structures possess an enormous interface area and provide highly conductive pathways for 
charge transport, useful to support neural network formation and neuronal regeneration. 
Several 3D scaffolds have been generated and tested in vitro, however so far only a 
very limited number of them have also been implanted in vivo (Figure 4). Some examples 
include G-coated electrospun PCL microfiber scaffolds, which were implanted in the 
striatum or the subventricular zone of adult rats. G-coated implants were associated with a 
lower microglia/macrophage infiltration when compared to bare scaffolds, while 
supporting astrocytes and neuroblast migration from the SVZ (Zhou et al., 2016). Free-
standing 3D GO porous scaffolds were implanted in the injured rat spinal cord, showing 
no local or systemic toxicity and a good biocompatibility also in the case of chronic 
implantation (Lopez-Dolado et al., 2015). Of note, long-term (30 days) implants were able 
to promote angiogenesis and partial axonal regeneration (Lopez-Dolado et al., 2016). No 
attempts have been made so far to use G-based materials to drive peripheral nervous system 
regeneration. A first step in this direction is represented by the engineering of G-silk fibroin 
composite nanofiber membranes. This composite material is of interest as it combines the 
electrical conductivity and mechanical strength of G with the good compatibility of silk. 
Although they have not been tested in vivo, G-silk membranes support the growth of 
Schwann cells in vitro (Zhao et al., 2017). 
Various three-dimensional G and GO foams were shown to be compatible substrates 
for stem cells (Crowder et al., 2013;Li et al., 2013a;Serrano et al., 2014;Guo et al., 
2016;Sayyar et al., 2016). Li et al. firstly described 3D G-based foams (3D-GFs) as suitable 
scaffold for neural stem cells (NSCs) growth and proliferation. NSCs grown on 3D-GFs 
were able to differentiate into neurons and astrocytes; moreover, it was also noticed that 
3D-GFs were optimal platforms for electrical stimulation of NSCs in order to enhance their 
differentiation (Li et al., 2013a). Similar results have been obtained more recently with 
rGO microfibers, which could support NSC viability and drive them toward a neuronal 
phenotype (Guo et al., 2017). Interestingly, the features of the G scaffolds (i.e. stiff vs soft) 
differentially affected cell adhesion and proliferation and could drive neural stem cell 
differentiation toward the astrocyte and neuronal lineages, respectively (Ma et al., 2016). 
Hippocampal neurons cultured on 3D-GFs are characterized by a more extensive 
connectivity associated to a higher network synchronization with respect to 2D-G 
substrates, thus better mimicking the physiological properties of the brain (Ulloa Severino 
et al., 2016). Microglial cells were also grown on 3D G foams. In this case, the 3D structure 
of the scaffolds affected the neuroinflammatory response of the cultured cells, probably 
because of spatial constraints due to the 3D topographic features (Song et al., 2014). 
Similar to what described for 2D materials, also 3D G/GO scaffolds were used as cell 
stimulating electrodes, to drive neuronal growth and differentiation of NSCs (Li et al., 
2013a;Akhavan et al., 2016). 
A new generation of electro responsive 3D-G scaffolds is also being developed, i.e. G-
based hydrogels, which mimic soft tissue and have been proposed for controlled, 
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stimulation-triggered drug release applications. Hybrid G-based hydrogels are synthetized 
mainly using GO, G oxide peroxide (GOP) or rGO, by incorporating very low amounts of 
the material into a hydrogel matrix, to enhance its electrical, mechanical and thermal 
properties (Servant et al., 2014b). Such materials are able to support neuronal growth and 
the development of synaptic activity (Martin et al., 2017). Following a similar approach, 
dexamethasone, a corticosteroid medication, was loaded onto poly(lactic-co-glycolic) acid 
NPs that were subsequently added into alginate hydrogels. The final composite was used 
as coating of gold and iridium electrodes for local drug administration after implantation 
(Kim et al., 2004;Kim and Martin, 2006). These or similar strategies could be employed to 
engineer smart coating for neuronal implants, with the final goal of having a device able to 
release biologically active molecules upon controlled electrical stimuli, at the same time 
improving the surface softness and enhancing the biocompatibility of the implants. 
Altogether, the use of G materials in 3D implants aimed at neuroscience applications 
is still limited. However, much is to be learnt from other fields of biomedicine. For 
example, G-hydrogels and foams have recently been proposed for anticancer therapy (Xu 
et al., 2017;Zhang et al., 2017), as well as for guided bone (Lu et al., 2016), cartilage (A. 
Nieto, 2015) and muscle (Mahmoudifard et al., 2016) regeneration. We expect that the 
cross-fertilization between these different disciplines will lead in the close future to the 
development of functional 3D, G-based implants for nervous system applications. 
 
 
 
 
Figure 4. 3D G-scaffolds in vitro and in vivo. (A) (a) SEM images of NSCs cultured on 
3D-G foams under proliferation conditions. The insets illustrate the interaction between the 
cell filopodia and surface. (b) Fluorescence images of NSCs cultured on 3D-G foams for 5 
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days. Nestin (green) is a marker for neural stem cells, and DAPI (blue) identifies nuclei. 
Modified with permission from Li et al. (Li et al., 2013a). (B) (a,b) Brain astrocyte/G-
scaffolds interaction and astrocyte process infiltration 3 weeks after scaffold implantation. 
Green: GFAP-positive astrocytes, blue: DAPIstained nucleus, red: surface-functionalized 
scaffolds. (b) Detailed astrocyte morphology of the dash-box indicated area in (a). * 
indicate astrocytes that bridge a gap between two scaffold layers. Scale bar, 50 (a) and 20 
(b) µm. Modified with permission from Zhou et al.(Zhou et al., 2016) 
 
3.2 Graphene-based devices for neural recording and stimulation. 
Clinical interventions for the recovery of neural dysfunctions and motor disorders 
attract and challenge the research toward implantable stimulation devices able to adapt to 
flexible supports and possibly outperform the most common metal electrode-based 
technologies. Polymeric interfaces outperform in terms of mechanically compliant 
properties, but often lack durability under physiological conditions, and, above all, proper 
electrical conductivity. Most of the neural stimulation performed so far with G-based 
electrodes in contact with living neuronal tissues or cells has been limited to modulate their 
growth and/or differentiation (Thompson et al., 2015). 
Neural stimulation techniques, such as deep brain or cortical stimulation, cochlear and 
retinal implants, usually rely on the ability of the implanted devices to elicit a functional 
response of the tissue by providing minimum injected charge, and therefore require 
electrodes (Kostarelos et al., 2017). To date, in vivo studies show that G electrodes can 
stimulate and record neuronal activity. G electrodes produce slightly higher values of 
charge injection with respect to common noble metal electrodes, like Pt or Au. New 
promising materials and compounds exploit G to reach up to tens of mC cm-2 charge 
injection levels, like in the case of an in vivo probe of laser reduced GO embedded into 
parylene-C (N. V. Apollo, 2015). The authors employ the novel flexible freestanding 
electrodes both to stimulate retinal ganglion cells ex vivo as much as to record neural 
activity in vivo from cat visual cortex. This constitutes one of the few reported evidences 
of neural stimulation with a G-based device. Other interesting applications make use of 
copper microwires encapsulated with CVD-G for an MRI compatible neural device (Zhao 
et al., 2016b), or flexible G micro-transistors for the mapping of brain activity (Blaschke, 
2016) just to mention a few, but still limited to the recording of neural activity in vivo. In 
addition, Kuzum and colleagues (Kuzum et al., 2014) also developed a flexible, low noise 
G electrode for simultaneous electrophysiology and imaging recording in vivo. After 
bicuculline injection to evoke epileptiform activity, it was possible to register 
simultaneously from rat cortical hemispheres with G electrodes and Au electrodes of the 
same size. The G electrodes showed 6 times lower SNR with respect to Au electrodes, 
suggesting that the adoption of the new G-based recording system could offer clear 
advantages for studying brain electrical activity. In addition, thanks to the transparency of 
the G electrodes, it was also possible to image the cortical area, combining in vivo two-
photon imaging and cortical electrophysiological recording (Kuzum et al., 2014). 
A further progress has been achieved by developing G field-effect transistors (G-FETs), 
which allow signal amplification reducing external noise (Veliev et al., 2017). Flexible G-
based supercapacitors showed recently their potential for neural stimulation thanks to their 
improved double layer capacitance when hybridized with polymeric materials, like 
PEDOT:PSS and rGO, G-polyaniline nanocomposites or CVD GO foams (Yang et al., 
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2015b;Hu et al., 2016). Nevertheless, most of these efforts need yet to be translated into 
usable electrodes for neuroscience applications. Another way to exploit G in bio-medical 
applications has been to enhance the optoelectronic properties of photosensitive neural 
interfaces deputed to the recovery of compromised vision. A polyimide array of 
photodetectors based on MoS2 and inkjet G has recently been proposed as flexible retinal 
prosthesis, and tested for biocompatibility in vitro (Hossain, 2017).  
In this framework, extensive reports demonstrate the ability of G to enhance organic 
photovoltaic devices. Diverse strategies have been followed to realize G-based solar cells, 
ranging from the modification of the anode electrode with GO (Rafique et al., 2017), to the 
realization of novel polymeric compounds containing GO-flakes or G quantum dots to 
improve charge carrier mobility or charge separation (Novak et al., 2016;Ye, 2016). These 
results depict a promising pathway to exploit the G electrical properties for biological 
applications. 
 
 
 
Figure 5. Graphene electrodes for in vivo recording. (A) Schematic illustration of a 
flexible G neural electrode array. (b) Photograph of a 16-electrode transparent array. The 
electrode size is 300 × 300 µm2. (B) (a) Photograph of a 50 × 50 µm2 single-G electrode 
placed on the cortical surface of the left hemisphere and a 500 × 500 µm2 single-Au 
electrode placed on the cortical surface of the right hemisphere. (b) Interictal-like spiking 
activity recorded by 50 × 50 µm2 doped-G and Au electrodes. Recordings with doped-G 
electrodes are five- to sixfold less noisy compared with the ones with same size Au 
electrode. Modified with permission from Kuzum et al. (Kuzum et al., 2014) 
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4. Computational modeling and simulations of Graphene-interacting 
biomolecular systems 
Understanding the fine structural details underlying interactions between biomolecules 
and inorganic surfaces is pivotal for many applications in nanomedicine. Although 
relevant experimental results about the dynamics of these interactions have been recently 
reported, many topological details remain unclear, especially at the initial events at ns 
to µs timescales. To fill this gap, the use of computational modeling and Molecular 
Dynamics (MD) simulations gives a relevant contribution, providing details that cannot 
be accessed by experimental techniques (Ozboyaci et al., 2016). 
With its promising properties, G has shown great potential in various applications, and 
the number of computational studies devoted to it is in constant growth (Cavallucci, 2016). 
Classical MD simulations (i.e. based on a classical physics description of atom-atom 
interactions) produced in the recent years a large amount of results on the interaction 
between G-based materials and biomolecules. In particular, these studies allowed to deeply 
characterize G as a substrate or nanopore for the deposition of biomolecules, 
differentiating the behavior of pristine G from that of GO. Moreover, MD simulations have 
been widely used to test G biocompatibility by studying its interaction with different 
biological structures such as membranes and protein complexes. In these studies, G has 
been described as a promising vector against bacterial agents as well as a material capable 
of perturbing biological complexes. 
The most important problem in classical simulations of these systems, still now under 
debate, is the definition of an appropriate set of force fields parameters for G, to allow the 
implementation of successful simulations with mainstream software packages used for 
the simulations of biological systems, e.g. GROMACS, ( Abr aham,  2015) , 
CHARMM ( B r o o k s  e t  a l . ,  2 0 0 9 )  or NAMD ( P h i l l i p s  e t  a l . ,  2 0 0 5 ) . 
Although different choices have been investigated, it is commonly accepted to describe G 
atoms as uncharged Lennard-Jones spheres ( H u m m e r  e t  a l . ,  2 0 0 1 ; P a t r a  
e t  a l . ,  2 0 0 9 ; P a t r a  e t  a l . ,  2 0 1 1 ) .  A list of G parameters used in different 
force fields has been recently reported (Pykal et al., 2016). The aim of this paragraph is to 
summarize the major findings of computational studies on the interactions between G-
based materials and biomolecules, broadly studied at a multi-scale level. A variety of 
different approaches have been used, such as all-atom or coarse-grained models, and 
different functional forms and parameters for interactions (the so-called force fields). 
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A general problem in computational biophysics is the gap between the size and 
time-scale that can be investigated by simulations and those of biologically relevant 
mechanisms. Molecular modeling is able to describe biological systems with all-atom 
details, but this limits its application to study systems of at most ~150 nm and on the 
microsecond time-scale. A possible way to bridge this gap is to use coarse-grained 
molecular dynamics (CGMD) simulations, which are based on a controlled reduction of 
the number of degrees of freedom and the use of shorter-range interacting functions. Due 
to these simplifications, a CG simulation has a minor resolution but requires less 
computational resources, allowing the study of larger systems for longer time-scales. A 
promising approach is to employ a multi-scale description, by alternating the use of 
classical all-atom with CGMD simulations. 
Several computational studies about G-biomolecules systems have been recently 
published, which can be grouped in the following thematic areas: 
 
1. the adsorption of proteins and peptides (with a particular interest for enzymes 
and blood proteins) on G substrates, in the context of the study of functional 
architectures for biomedical applications. Results show that GO has a good 
solubility in aqueous solution and other organic solvents, thanks to the oxygen-
containing groups which can act as reaction sites for the binding of different 
molecules. As an example, the immobilization of enzymes on a solid substrate is 
an efficient process to improve its activity while a major factor determining the 
biocompatibility of a nanomaterial in contact with blood, e.g. medical implants, is 
the adsorption of proteins on its surface. 
 
2. the interaction of G with biomembranes to assess biological safety or toxicity 
of G, as well as its promising function as a vector of new classes of antibiotics. 
 
3. DNA or protein detection by G nanopores, an encouraging class of nanosensors 
that are less sensitive than biological pores to various factors such as the 
temperature and pH. 
 
In the next paragraph, we describe in more detail some of the studies of points 1 and 2 
above, while for those in point 3 we refer the interested reader to the following works 
for the study of DNA detection (Sathe et al. , 2011;Wells et al.,  2012;Sathe et 
al.,  2014;Qiu et al. , 2015;Barati Farimani et al.,  2017) and for the study of 
protein detection to Farimani et al. (Barati Farimani, 2017). 
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5. Adsorption of biomolecules onto Graphene. 
 
5.1. Pristine Graphene substrates. 
One of the first efforts of all-atom MD simulations for the study of protein adsorption 
is described in (Zuo, 2011) where the adsorption of the headpiece (HP35) of villin was 
studied. The simulations showed a rapid adsorption of HP35 by the substrate with relevant 
conformational changes in both the secondary and tertiary structures. The π/π stacking 
interactions between aromatic residues and G dominate the protein-G interaction 
differently from other HP35- curved carbon nanostructures. At a later time, Zhou and 
collaborators (Gu et al., 2015) performed MD simulations to show how blood proteins such 
as bovine fibrinogen (BFG) can rapidly adsorb onto the G surface. Markedly, these 
simulations describe, in addition to the aforementioned effect of strong π/π stacking 
interactions, another key interaction due to basic residues. These residues play a relevant 
role during the process because of the strong dispersion interactions between their side-
chains and the substrate. Globally, hydrophobic, electrostatic and π/π stacking interactions 
drive the immobilization of the molecule on G. 
In the same year, Kim et al. (Kim et al., 2015) examined the recognition of G by 
peptides with respect to the chemical composition of G, the number of overimposed layers, 
and the underlying substrate support. The results of this computational work, together with 
experimental data based on Resonance Raman Spectroscopy, Quartz Crystal 
Microbalance, and Water Contact Angle measurements, indicate that G quality is a 
significant factor in G- peptide interactions, while the interaction appears to show no 
significant dependency on the number of G layers or the underlying support substrate. More 
recently (No et al., 2017) reported nature-inspired two-dimensional peptide self-assembly 
on G via optimization of peptide−peptide and peptide−G interactions. Atomistic 
simulations determined the optimal peptide sequence that leads to peptide self-assembly 
on G, suggesting that the optimal peptide sequence minimizes the peptide−G interaction 
energy and also the peptide−peptide interaction energy, resulting in stable complexes on G. 
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6. GO substrates. 
The adhesion of biomolecules to GO and rGO layers was investigated in Chong et 
al., (Chong et al., 2015) to test the different advantages of GO due to the presence of the 
oxygen atoms. The interactions of serum proteins with GO nanosheets were explored with 
a large set of experimental techniques and with MD simulations, showing high adsorption 
capacities of GO and rGO. However, it is important to point out that while GO and rGO 
were used in the experiments, pristine G was chosen to simulate the relevant non-oxidized 
regions of the surface present on GO nanosheets. The action of GO was investigated more 
explicitly by representing the substrate using the Lerf-Klinowski model (Lerf, 1998), which 
describes the behavior of a standard oxidation process. Using this approach, two 
paradigmatic papers (Sun et al., 2014;Zeng et al., 2016) demonstrated that GO displays 
an enhanced adsorption of the attached protein. Firstly, in Sun et al. (Sun et al., 2014), an 
atomistic description of the inhibitory action of GO on the activity of α-chymotrypsin 
(ChT), has been provided. The results support the hypothesis that GO can be considered 
as a promising receptor for enzyme inhibition. Secondly, Zeng et al. (Zeng et al., 2016) 
show the details of the binding energy of GO to Vpr13-33, a fragment of the viral protein 
R (Vpr), using potential of mean force (PMF) calculations with the enhanced method 
umbrella sampling (Kästner, 2011). 
Recently, Willems et al. (Willems et al., 2017) investigated the dynamics of supported 
phospholipid membrane patches stabilized on G surfaces. These systems show potential 
in sensor device functionalization. The authors integrated experimental measures and 
CGMD simulations to characterize the molecular properties of supported lipid membranes 
(SLMs) on G and GO supports. The results described substantial differences in the 
topologies of the stabilized lipid structures, depending on the nature of the surface, 
providing novel details into the molecular effects of G and G oxide surfaces on lipid 
membranes. 
Overall, parallel to this considerable amount of data, in this emerging area of 
computational applications many fundamental issues remain unresolved, due to the 
lack of sufficient experimental results. In particular, the detailed distribution of the oxygen-
containing groups on the substrate is difficult to determine, with a considerable loss in the 
description of the adsorption mechanism. 
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7. Interactions of Graphene with biomembranes. 
The interaction of G with biomolecular complexes is crucial to understand its 
biological safety and potential toxicity. A seminal work (Tu et al., 2013) showed 
that GR and GO nanosheets induce the degradation of the inner and outer cell 
membranes of Escherichia Coli. Specifically, MD simulations showed that G is able 
to actively extract phospholipid molecules from a lipid bilayer, fixing them on its 
surface. Although these results introduce G as a convenient tool able to kill bacteria, 
there is an abundant literature where G also shows destructive capacities towards some 
biomolecules (Luan et al., 2015). 
In this context, the results from CGMD simulations describe a quite different 
scenario. One of the first uses of CGMD for studying G-biomolecules interactions can 
be found in (Titov et al., 2010). There, the Martini force field (Marrink et al., 2007) is 
used to study the interaction of G nanosheets with phospholipid bilayers formed by 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine  (POPC membrane). Results showed 
that G sheets are hosted in the hydrophobic interior of the membrane, forming stable 
G-lipid structures (Figure 6). 
 
 
 
Figure 6. Graphene interaction with biomembranes. (A) Equilibrated superstructure 
of a graphene sheet inside the phospholipid bilayer formed by POPC lipids. Polar heads 
of the POPC lipids are depicted as green beads, hydrophobic hydrocarbon chains as 
thick blue lines; the graphene sheet is shown with brown lines (water molecules not 
shown; modified with permission from Titov et al., (Titov et al., 2010)). (B) The 
structure of single (A) and double (B) Cldn15-based paracellular pores, after the 
respective equilibration protocols. Protomers are shown as ribbons. Each cis dimer is 
embedded in a hexagonal POPC bilayer, shown as wire structures with phosphorus 
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atoms as spheres. Modified with permission from Alberini et al. (Alberini et al., 2017) 
 
In the following years, other works have investigated these systems with various 
CGMD algorithms, such as Guo et al. (Guo et al., 2013), Mao et al. (Mao et al., 2014) 
and Li et al. (Li et al., 2013b). In all these studies, however, lipid extraction or 
membrane damage is not observed, in contrast to the results of Tu et al. (Tu et al., 
2013). More recently, computational simulations were used to elucidate whether G 
causes cell membrane damage (Chen, 2016). All-atom MD simulations were used to 
study the interaction of both G and GO with respect to a 
dipalmitoylphosphatidylcholine (DPPC) bilayer, and they revealed that G quickly 
enters into the membrane by assuming a position parallel to the lipid tails. Conversely, 
GO did not enter the membrane spontaneously during the observed time-scale, but 
when docked onto the bilayer, it formed pores in the membrane. 
A particularly important biomembrane system is the one involved in the formation 
of biological barriers such as for example the blood-brain barrier (BBB). 
Computational studies can be useful to investigate the effect of barrier exposure to G-
based materials (Figure 5), but studying such complex architectures is still 
hampered by the lack of structural information (Alberini et al., 2017). 	 	
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8 Conclusions: future challenges and perspectives 
In the past few years, GRMs have been studied and used in a wide range of 
technological fields, including biomedical applications. The treatment of neurological 
disorders through non-invasive pharmacological approaches is still a major challenge. 
It is crucial for scientist to develop strategies for efficient cargo delivery of drugs or 
biomolecules or even genes to the brain, bypassing the BBB while preserving its 
structure and vital functions. One of the purposes of nanomedicine is indeed to create 
innovative ways for cell-targeting and drug-controlled release by avoiding surgery or 
other approaches that are very invasive for the patient. In this scenario, the choice of 
the appropriate ligand-receptor complex is a key design element when constructing 
nano-carriers, as well as the choice of the material, the size and eventual 
functionalization. While receptor-mediated transcytosis is a fundamental pathway for 
BBB crossing, the development of next-generation nano-carriers, like 2D-materials, 
and the investigation and optimization of alternative routes for delivery, such as 
intranasal administration, is of utmost importance for the scientific community. 
Besides the ‘BBB challenge’, other aspects of neuroscience could benefit of the latest 
developments in graphene research. Neuro-oncology may profit from the development 
of G nanosheets and G nanoparticles for tumor-targeted imaging, photothermal therapy, 
and anticancer drug delivery and gene therapy. New electrical, chemical and optical 
sensors may have great impact for neuro-intensive care and neuro-monitoring. 
Moreover, the combination of different forms and states of G, diverse chemical 
functionalization and the possible association with other biomaterials to form G-based 
composites, may allow to devise an all-in one tool for both diagnosis and therapy, thus 
effectively building a powerful theranostic device. 
Finally, tissue-engineering research is expected to develop novel brain-implant 
interfaces based on G, to exploit the material electrical conductivity and enhance cell-
cell communication and repair. Besides the experimental and clinical evidence, 
molecular dynamics studies are emerging as an important aspect of material research, 
as they provide extremely precise indications and predictions on G/cell and G/protein 
interactions, guiding the researcher to design more powerful G-based devices. 
Nevertheless, despite initial studies demonstrated the biocompatibility of G, especially 
when conjugated with other materials in 2D and 3D scaffolds, only few systems were 
demonstrated to be successful in vivo. Further investigations are still required, in 
particular about the biological effects of long-term treatment with G materials, before 
the promised technological applications can be fully exploited in and beyond 
neuroscience. 
 
  
	 27	
 
Acknowledgements 
The authors acknowledge financial support from EU H2020 research and innovation 
programme under grant agreement no. 696656 (Graphene Flaghship – Core1). 
 
  
	 28	
References A.	 Nieto,	 R.D.,	 C.	 Zhang,	 B.	 Boesl,	 S.	 Ramaswamy,	 A.	 Agarwal	 (2015).	 Three	Dimensional	 Graphene	 Foam/Polymer	 Hybrid	 as	 a	 High	 Strength	Biocompatible	Scaffold.	Adv.	Funct.	Mater.	25,	3916-3924.	Abbott,	N.J.	(2013).	Blood-brain	barrier	structure	and	function	and	the	challenges	for	CNS	drug	delivery.	J	Inherit	Metab	Dis	36,	437-449.	Abbott,	N.J.,	Patabendige,	A.A.,	Dolman,	D.E.,	Yusof,	S.R.,	and	Begley,	D.J.	 (2010).	Structure	and	function	of	the	blood-brain	barrier.	Neurobiol	Dis	37,	13-25.	Abbott,	N.J.,	and	Romero,	I.A.	(1996).	Transporting	therapeutics	across	the	blood-brain	barrier.	Mol	Med	Today	2,	106-113.	Abbott,	 N.J.,	 Ronnback,	 L.,	 and	 Hansson,	 E.	 (2006).	 Astrocyte-endothelial	interactions	at	the	blood-brain	barrier.	Nat	Rev	Neurosci	7,	41-53.	Åberg,	C.	(2016).	Quantitative	analysis	of	nanoparticle	transport	through	in	vitro	blood-brain	barrier	models.	Tissue	Barriers	4,	e1143545.	Abraham,	M.J.,	 Murtola,	 T.,	 Schultz,	 R.,	 Pall,	 S.,	 Smith,	 J.	 C.,	 Hess,	 B.,	 Lindahlad-Gromacs,	E.	 (2015).	High	performance	molecular	 simulations	 through	multi-level	parallelism	from	laptops	to	supercomputers.	SoftwareX	1-2,	19-25.	Akhavan,	O.,	Ghaderi,	E.,	Shirazian,	S.A.,	and	Rahighi,	R.	(2016).	Rolled	graphene	oxide	 foams	as	 three-dimensional	scaffolds	 for	growth	of	neural	 fibers	using	electrical	stimulation	of	stem	cells.	Carbon	97,	71-77.	Alberini,	G.,	Benfenati,	F.,	and	Maragliano,	L.	(2017).	A	refined	model	of	claudin-15	tight	 junction	 paracellular	 architecture	 by	 molecular	 dynamics	 simulations.	
PLoS	One	12,	e0184190.	Allen,	 T.M.,	 and	 Cullis,	 P.R.	 (2004).	 Drug	 delivery	 systems:	 entering	 the	mainstream.	Science	303,	1818-1822.	Ambrosi,	A.,	and	Pumera,	M.	(2016).	Electrochemically	Exfoliated	Graphene	and	Graphene	 Oxide	 for	 Energy	 Storage	 and	 Electrochemistry	 Applications.	
Chemistry	22,	153-159.	Andrieux,	K.,	and	Couvreur,	P.	 (2009).	Polyalkylcyanoacrylate	nanoparticles	 for	delivery	of	drugs	across	the	blood-brain	barrier.	Wiley	Interdiscip	Rev	Nanomed	
Nanobiotechnol	1,	463-474.	Baldrighi,	M.,	Trusel,	M.,	Tonini,	R.,	and	Giordani,	S.	(2016).	Carbon	Nanomaterials	Interfacing	with	Neurons:	An	In	vivo	Perspective.	Front	Neurosci	10,	250.	Barati	Farimani,	A.,	Dibaeinia,	P.,	and	Aluru,	N.R.	(2017).	DNA	Origami-Graphene	Hybrid	Nanopore	for	DNA	Detection.	ACS	Appl	Mater	Interfaces	9,	92-100.	Barati	Farimani,	A.,	Heiranian,	M.,	Min,	K.,	Aluru,	N.	R.	(2017).	Antibody	Subclass	Detection	Using	Graphene	Nanopores.	J.	Phys.	Chem.		Lett.	8,	1670-1676.	Begley,	D.J.	(2004).	ABC	transporters	and	the	blood-brain	barrier.	Curr	Pharm	Des	10,	1295-1312.	Begley,	D.J.,	and	Brightman,	M.W.	(2003).	Structural	and	functional	aspects	of	the	blood-brain	barrier.	Prog	Drug	Res	61,	39-78.	Bianco,	 A.	 (2013).	 Graphene:	 safe	 or	 toxic?	The	 two	 faces	of	 the	medal.	Angew	
Chem	Int	Ed	Engl	52,	4986-4997.	Bitounis,	 D.,	 Ali-Boucetta,	 H.,	 Hong,	 B.H.,	 Min,	 D.H.,	 and	 Kostarelos,	 K.	 (2013).	Prospects	and	challenges	of	graphene	in	biomedical	applications.	Adv	Mater	25,	2258-2268.	Blaschke,	B.M.L.,	M.;	Drieschner,	S.;	Bonaccini	Calia,	A.;	Stoiber,	K.;	Rousseau,	L.;	Lissourges,	G.;	Garrido,	J.A.	(2016).	Flexible	graphene	transistor	for	recording	cell	action	potentials.	2d	Mater	3,	025007.	
	 29	
Bonaccorso,	 F.,	 Bartolotta,	 A.,	 Coleman,	 J.N.,	 and	 Backes,	 C.	 (2016).	 2D-Crystal-Based	Functional	Inks.	Adv	Mater	28,	6136-6166.	Bonaccorso,	F.,	Colombo,	L.,	Yu,	G.,	Stoller,	M.,	Tozzini,	V.,	Ferrari,	A.C.,	Ruoff,	R.S.,	and	 Pellegrini,	 V.	 (2015).	 2D	 materials.	 Graphene,	 related	 two-dimensional	crystals,	and	hybrid	systems	for	energy	conversion	and	storage.	Science	347,	1246501.	Bramini,	 M.,	 Alberini,	 G.,	 Benfneati,	 F.,	 Maragliano,	 L.,	 Cesca,	 F.	 (2018).	"Interactions	Between	2D	Graphene-Based	Materials	and	the	Nervous	Tissue,"	in	2D	Materials:	Characterization,	Production	and	Application,	ed.	C.E.B.a.D.a.C.	Brownson.	CRC	Press	(Taylor	&	Francis	Group)),	62-85.	Bramini,	M.,	Sacchetti,	S.,	Armirotti,	A.,	Rocchi,	A.,	Vazquez,	E.,	Leon	Castellanos,	V.,	Bandiera,	T.,	Cesca,	F.,	 and	Benfenati,	 F.	 (2016).	Graphene	Oxide	Nanosheets	Disrupt	Lipid	Composition,	Ca(2+)	Homeostasis,	and	Synaptic	Transmission	in	Primary	Cortical	Neurons.	ACS	Nano	10,	7154-7171.	Bramini,	 M.,	 Ye,	 D.,	 Hallerbach,	 A.,	 Nic	 Raghnaill,	 M.,	 Salvati,	 A.,	 Aberg,	 C.,	 and	Dawson,	K.A.	 (2014).	 Imaging	approach	to	mechanistic	study	of	nanoparticle	interactions	with	the	blood-brain	barrier.	ACS	Nano	8,	4304-4312.	Brooks,	B.R.,	Brooks,	C.L.,	3rd,	Mackerell,	A.D.,	Jr.,	Nilsson,	L.,	Petrella,	R.J.,	Roux,	B.,	Won,	 Y.,	 Archontis,	 G.,	 Bartels,	 C.,	 Boresch,	 S.,	 Caflisch,	 A.,	 Caves,	 L.,	 Cui,	 Q.,	Dinner,	 A.R.,	 Feig,	 M.,	 Fischer,	 S.,	 Gao,	 J.,	 Hodoscek,	 M.,	 Im,	W.,	 Kuczera,	 K.,	Lazaridis,	 T.,	Ma,	 J.,	 Ovchinnikov,	 V.,	 Paci,	 E.,	 Pastor,	 R.W.,	 Post,	 C.B.,	 Pu,	 J.Z.,	Schaefer,	M.,	Tidor,	B.,	Venable,	R.M.,	Woodcock,	H.L.,	Wu,	X.,	Yang,	W.,	York,	D.M.,	and	Karplus,	M.	(2009).	CHARMM:	the	biomolecular	simulation	program.	
J	Comput	Chem	30,	1545-1614.	Casaluci,	 S.,	 Gemmi,	 M.,	 Pellegrini,	 V.,	 Di	 Carlo,	 A.,	 and	 Bonaccorso,	 F.	 (2016).	Graphene-based	 large	 area	 dye-sensitized	 solar	 cell	 modules.	 Nanoscale	 8,	5368-5378.	Cavallucci,	 T.K.,	 K.;	 Farchioni,	 R.;	 Tozzini,	 V.	 (2016).	Morphing	 graphene-based	systems	for	applications:	perspectives	from	simulation.	arXiv:1609.07871.	Chang,	 E.F.	 (2015).	 Towards	 large-scale,	 human-based,	 mesoscopic	neurotechnologies.	Neuron	86,	68-78.	Chen,	B.L.,	M.;	Zhang,	L.;	Huang,	 J.;	Yao,	 J.;	 Zhang,	Z.	 (2011).	polyethyleniimine-functionalized	 graphene	 oxide	 as	 an	 efficient	 gene	 delivery	 vector.	 J.	 Mater.	
Chem.	11,	7736-7741.	Chen,	G.Y.,	Chen,	C.L.,	Tuan,	H.Y.,	Yuan,	P.X.,	Li,	K.C.,	Yang,	H.J.,	and	Hu,	Y.C.	(2014).	Graphene	oxide	triggers	toll-like	receptors/autophagy	responses	in	vitro	and	inhibits	tumor	growth	in	vivo.	Adv	Healthc	Mater	3,	1486-1495.	Chen,	J.Z.,	G.;	Chen,	L.;	Wang,	Y.;	Wang,	X.;	Zeng,	S.	(2016).	Interaction	of	Graphene	and	its	Oxide	with	Lipid	Membrane:	A	Molecular	Dynamics	Simulation	Study.	J.	
Phys.	Chem.	C	120,	6225-6231.	Chen,	 M.,	 Yin,	 J.,	 Liang,	 Y.,	 Yuan,	 S.,	 Wang,	 F.,	 Song,	 M.,	 and	 Wang,	 H.	 (2016).	Oxidative	stress	and	immunotoxicity	induced	by	graphene	oxide	in	zebrafish.	
Aquat	Toxicol	174,	54-60.	Chen,	R.C.,	A.;	Anikeeva	P.	(2017).	Neural	recording	and	modulation	technologies.	
Nature	Reviews	Materials	2	2,	16093.	Chen,	Y.,	Star,	A.,	and	Vidal,	S.	(2013).	Sweet	carbon	nanostructures:	carbohydrate	conjugates	with	carbon	nanotubes	and	graphene	and	their	applications.	Chem	
Soc	Rev	42,	4532-4542.	
	 30	
Cheng,	 C.L.,	 S.;	 Thomas,	 A.;	 Kotov,	 A.N.;	 Haag,	 R.	 (2016).	 Functional	 Graphene	Nanomaterials	 Based	 Architectures:	 Biointeractions,	 Fabrications,	 and	Emerging	Biological	Applications.	Chem.	Rev.	117,	1826-1914.	Choi,	 M.,	 Ku,	 T.,	 Chong,	 K.,	 Yoon,	 J.,	 and	 Choi,	 C.	 (2011).	 Minimally	 invasive	molecular	 delivery	 into	 the	 brain	 using	 optical	 modulation	 of	 vascular	permeability.	Proc	Natl	Acad	Sci	U	S	A	108,	9256-9261.	Chong,	Y.,	Ge,	C.,	Yang,	Z.,	Garate,	J.A.,	Gu,	Z.,	Weber,	J.K.,	Liu,	J.,	and	Zhou,	R.	(2015).	Reduced	 Cytotoxicity	 of	 Graphene	 Nanosheets	 Mediated	 by	 Blood-Protein	Coating.	ACS	Nano	9,	5713-5724.	Chowdhury,	 I.,	 Duch,	 M.C.,	 Mansukhani,	 N.D.,	 Hersam,	 M.C.,	 and	 Bouchard,	 D.	(2013).	Colloidal	properties	and	stability	of	graphene	oxide	nanomaterials	in	the	aquatic	environment.	Environ	Sci	Technol	47,	6288-6296.	Clark,	 A.J.,	 and	 Davis,	 M.E.	 (2015).	 Increased	 brain	 uptake	 of	 targeted	nanoparticles	by	adding	an	acid-cleavable	linkage	between	transferrin	and	the	nanoparticle	core.	Proc	Natl	Acad	Sci	U	S	A	112,	12486-12491.	Cong,	H.P.,	Chen,	J.F.,	and	Yu,	S.H.	(2014).	Graphene-based	macroscopic	assemblies	and	architectures:	an	emerging	material	system.	Chem	Soc	Rev	43,	7295-7325.	Crowder,	S.W.,	Prasai,	D.,	Rath,	R.,	Balikov,	D.A.,	Bae,	H.,	Bolotin,	K.I.,	and	Sung,	H.J.	(2013).	Three-dimensional	graphene	foams	promote	osteogenic	differentiation	of	human	mesenchymal	stem	cells.	Nanoscale	5,	4171-4176.	Defterali,	 C.,	 Verdejo,	 R.,	 Peponi,	 L.,	 Martin,	 E.D.,	 Martinez-Murillo,	 R.,	 Lopez-Manchado,	M.A.,	and	Vicario-Abejon,	C.	(2016).	Thermally	reduced	graphene	is	a	permissive	material	for	neurons	and	astrocytes	and	de	novo	neurogenesis	in	the	adult	olfactory	bulb	in	vivo.	Biomaterials	82,	84-93.	Dell'orco,	 D.,	 Lundqvist,	 M.,	 Oslakovic,	 C.,	 Cedervall,	 T.,	 and	 Linse,	 S.	 (2010).	Modeling	the	time	evolution	of	the	nanoparticle-protein	corona	in	a	body	fluid.	
PLoS	One	5,	e10949.	Ding,	X.,	 Liu,	H.,	 and	Fan,	Y.	 (2015).	Graphene-Based	Materials	 in	Regenerative	Medicine.	Adv	Healthc	Mater	4,	1451-1468.	Dohgu,	S.,	Takata,	F.,	Yamauchi,	A.,	Nakagawa,	S.,	Egawa,	T.,	Naito,	M.,	Tsuruo,	T.,	Sawada,	Y.,	Niwa,	M.,	and	Kataoka,	Y.	(2005).	Brain	pericytes	contribute	to	the	induction	 and	 up-regulation	 of	 blood-brain	 barrier	 functions	 through	transforming	growth	factor-beta	production.	Brain	Res	1038,	208-215.	Donaldson,	K.,	Aitken,	R.,	Tran,	L.,	Stone,	V.,	Duffin,	R.,	Forrest,	G.,	and	Alexander,	A.	 (2006).	 Carbon	 nanotubes:	 a	 review	 of	 their	 properties	 in	 relation	 to	pulmonary	toxicology	and	workplace	safety.	Toxicol	Sci	92,	5-22.	Dong,	H.,	Jin,	M.,	Liu,	Z.,	Xiong,	H.,	Qiu,	X.,	Zhang,	W.,	and	Guo,	Z.	(2016).	In	vitro	and	in	 vivo	 brain-targeting	 chemo-photothermal	 therapy	 using	 graphene	 oxide	conjugated	with	transferrin	for	Gliomas.	Lasers	Med	Sci	31,	1123-1131.	Du,	D.,	Zou,	Z.,	Shin,	Y.,	Wang,	J.,	Wu,	H.,	Engelhard,	M.H.,	Liu,	J.,	Aksay,	I.A.,	and	Lin,	Y.	(2010).	Sensitive	immunosensor	for	cancer	biomarker	based	on	dual	signal	amplification	 strategy	 of	 graphene	 sheets	 and	 multienzyme	 functionalized	carbon	nanospheres.	Anal	Chem	82,	2989-2995.	Dufficy,	 M.K.,	 Geiger,	 M.T.,	 Bonino,	 C.A.,	 and	 Khan,	 S.A.	 (2015).	 Electrospun	Ultrafine	Fiber	Composites	Containing	Fumed	Silica:	From	Solution	Rheology	to	Materials	with	Tunable	Wetting.	Langmuir	31,	12455-12463.	Eda,	 G.,	 Fanchini,	 G.,	 and	 Chhowalla,	 M.	 (2008).	 Large-area	 ultrathin	 films	 of	reduced	graphene	oxide	as	a	transparent	and	flexible	electronic	material.	Nat	
Nanotechnol	3,	270-274.	
	 31	
Ek,	 C.J.,	 Dziegielewska,	 K.M.,	 Stolp,	 H.,	 and	 Saunders,	 N.R.	 (2006).	 Functional	effectiveness	 of	 the	 blood-brain	 barrier	 to	 small	water-soluble	molecules	 in	developing	and	adult	opossum	(Monodelphis	domestica).	J	Comp	Neurol	496,	13-26.	El-Kady,	M.F.,	and	Kaner,	R.B.	(2013).	Scalable	fabrication	of	high-power	graphene	micro-supercapacitors	for	flexible	and	on-chip	energy	storage.	Nat	Commun	4,	1475.	Fabbro,	A.,	 Scaini,	D.,	 Leon,	V.,	Vazquez,	E.,	Cellot,	G.,	Privitera,	G.,	 Lombardi,	 L.,	Torrisi,	F.,	Tomarchio,	F.,	Bonaccorso,	F.,	Bosi,	S.,	Ferrari,	A.C.,	Ballerini,	L.,	and	Prato,	M.	(2016).	Graphene-Based	Interfaces	Do	Not	Alter	Target	Nerve	Cells.	
ACS	Nano	10,	615-623.	Fahmi,	T.,	Branch,	D.,	Nima,	Z.A.,	Jang,	D.S.,	Savenka,	A.V.,	Biris,	A.S.,	and	Basnakian,	A.G.	 (2017).	 Mechanism	 of	 graphene-induced	 cytotoxicity:	 Role	 of	endonucleases.	J	Appl	Toxicol	37,	1325-1332.	Feng,	L.,	Wu,	L.,	and	Qu,	X.	(2013).	New	horizons	for	diagnostics	and	therapeutic	applications	of	graphene	and	graphene	oxide.	Adv	Mater	25,	168-186.	Feng,	L.,	Zhang,	S.,	and	Liu,	Z.	(2011).	Graphene	based	gene	transfection.	Nanoscale	3,	1252-1257.	Gao,	X.,	Qian,	 J.,	 Zheng,	 S.,	 Changyi,	Y.,	 Zhang,	 J.,	 Ju,	 S.,	 Zhu,	 J.,	 and	Li,	C.	 (2014).	Overcoming	the	blood-brain	barrier	for	delivering	drugs	into	the	brain	by	using	adenosine	receptor	nanoagonist.	ACS	Nano	8,	3678-3689.	Geim,	A.K.	(2009).	Graphene:	status	and	prospects.	Science	324,	1530-1534.	Gelperina,	S.,	Maksimenko,	O.,	Khalansky,	A.,	Vanchugova,	L.,	Shipulo,	E.,	Abbasova,	K.,	 Berdiev,	 R.,	 Wohlfart,	 S.,	 Chepurnova,	 N.,	 and	 Kreuter,	 J.	 (2010).	 Drug	delivery	 to	 the	 brain	 using	 surfactant-coated	 poly(lactide-co-glycolide)	nanoparticles:	influence	of	the	formulation	parameters.	Eur	J	Pharm	Biopharm	74,	157-163.	Georgakilas,	V.,	Tiwari,	J.N.,	Kemp,	K.C.,	Perman,	J.A.,	Bourlinos,	A.B.,	Kim,	K.S.,	and	Zboril,	 R.	 (2016).	 Noncovalent	 Functionalization	 of	 Graphene	 and	Graphene	Oxide	for	Energy	Materials,	Biosensing,	Catalytic,	and	Biomedical	Applications.	
Chem	Rev	116,	5464-5519.	Goenka,	S.,	Sant,	V.,	and	Sant,	S.	(2014).	Graphene-based	nanomaterials	for	drug	delivery	and	tissue	engineering.	J	Control	Release	173,	75-88.	Gollavelli,	G.,	and	Ling,	Y.C.	(2012).	Multi-functional	graphene	as	an	in	vitro	and	in	vivo	imaging	probe.	Biomaterials	33,	2532-2545.	Gu,	Z.,	Yang,	Z.,	Wang,	L.,	Zhou,	H.,	Jimenez-Cruz,	C.A.,	and	Zhou,	R.	(2015).	The	role	of	basic	residues	in	the	adsorption	of	blood	proteins	onto	the	graphene	surface.	
Sci	Rep	5,	10873.	Guo,	R.,	Mao,	J.,	and	Yan,	L.T.	(2013).	Computer	simulation	of	cell	entry	of	graphene	nanosheet.	Biomaterials	34,	4296-4301.	Guo,	W.,	Qiu,	 J.,	Liu,	 J.,	and	Liu,	H.	 (2017).	Graphene	microfiber	as	a	scaffold	 for	regulation	of	neural	stem	cells	differentiation.	Sci	Rep	7,	5678.	Guo,	W.,	Wang,	S.,	Yu,	X.,	Qiu,	J.,	Li,	J.,	Tang,	W.,	Li,	Z.,	Mou,	X.,	Liu,	H.,	and	Wang,	Z.	(2016).	Construction	of	a	3D	rGO-collagen	hybrid	scaffold	for	enhancement	of	the	neural	differentiation	of	mesenchymal	stem	cells.	Nanoscale	8,	1897-1904.	Hassoun,	 J.,	Bonaccorso,	F.,	Agostini,	M.,	Angelucci,	M.,	Betti,	M.G.,	Cingolani,	R.,	Gemmi,	M.,	Mariani,	 C.,	 Panero,	 S.,	 Pellegrini,	 V.,	 and	 Scrosati,	 B.	 (2014).	 An	advanced	 lithium-ion	battery	based	on	a	graphene	anode	and	a	 lithium	 iron	phosphate	cathode.	Nano	Lett	14,	4901-4906.	
	 32	
Hatsopoulos,	 N.G.,	 and	 Donoghue,	 J.P.	 (2009).	 The	 science	 of	 neural	 interface	systems.	Annu	Rev	Neurosci	32,	249-266.	Hawkins,	R.A.,	O'kane,	R.L.,	Simpson,	 I.A.,	and	Vina,	 J.R.	 (2006).	Structure	of	 the	blood-brain	 barrier	 and	 its	 role	 in	 the	 transport	 of	 amino	 acids.	 J	Nutr	 136,	218S-226S.	Herda,	 L.M.,	 Polo,	 E.,	 Kelly,	 P.M.,	 Rocks,	 L.,	 Hudecz,	 D.,	 Dawson,	 K.A.	 (2014).	Designing	the	future	of	nanomedicine:	current	barriers	to	targeted	brain	therapeutics.	Eur.	J.	Nanomed.	6,	127-139.	Hess,	L.H.,	Jansen,	M.,	Maybeck,	V.,	Hauf,	M.V.,	Seifert,	M.,	Stutzmann,	M.,	Sharp,	I.D.,	Offenhausser,	 A.,	 and	 Garrido,	 J.A.	 (2011).	 Graphene	 transistor	 arrays	 for	recording	action	potentials	from	electrogenic	cells.	Adv	Mater	23,	5045-5049,	4968.	Honigsmann,	 H.	 (2013).	 History	 of	 phototherapy	 in	 dermatology.	 Photochem	
Photobiol	Sci	12,	16-21.	Hossain,	 R.F.,	 Deaguero,	 I.	G.,	 Boland,	T.	 And	Kaul,	 A.	 B.	 (2017).	 Biocompatible,	large-format,	inkjet	printed	heterostructure	MoS2-graphene	photodetectors	on	conformable	substrates.	npj	2D	Materials	and	Applications	28,	1-10.	Hsieh,	T.Y.,	Huang,	W.C.,	Kang,	Y.D.,	Chu,	C.Y.,	Liao,	W.L.,	Chen,	Y.Y.,	and	Chen,	S.Y.	(2016).	 Neurotensin-Conjugated	 Reduced	 Graphene	 Oxide	 with	 Multi-Stage	Near-Infrared-Triggered	Synergic	Targeted	Neuron	Gene	Transfection	In	Vitro	and	 In	 Vivo	 for	 Neurodegenerative	 Disease	 Therapy.	 Adv	 Healthc	 Mater	 5,	3016-3026.	Hu,	N.,	Zhang,	L.,	Yang,	C.,	Zhao,	 J.,	Yang,	Z.,	Wei,	H.,	Liao,	H.,	Feng,	Z.,	Fisher,	A.,	Zhang,	 Y.,	 and	 Xu,	 Z.J.	 (2016).	 Three-dimensional	 skeleton	 networks	 of	graphene	 wrapped	 polyaniline	 nanofibers:	 an	 excellent	 structure	 for	 high-performance	flexible	solid-state	supercapacitors.	Sci	Rep	6,	19777.	Hummer,	G.,	Rasaiah,	 J.C.,	and	Noworyta,	 J.P.	 (2001).	Water	conduction	through	the	hydrophobic	channel	of	a	carbon	nanotube.	Nature	414,	188-190.	Jiang,	Z.,	 Song,	Q.,	Tang,	M.,	Yang,	L.,	Cheng,	Y.,	 Zhang,	M.,	Xu,	D.,	 and	Cheng,	G.	(2016).	 Enhanced	 Migration	 of	 Neural	 Stem	 Cells	 by	 Microglia	 Grown	 on	 a	Three-Dimensional	 Graphene	 Scaffold.	 ACS	 Appl	 Mater	 Interfaces	 8,	 25069-25077.	John,	 A.A.,	 Subramanian,	 A.P.,	 Vellayappan,	 M.V.,	 Balaji,	 A.,	 Mohandas,	 H.,	 and	Jaganathan,	 S.K.	 (2015).	 Carbon	 nanotubes	 and	 graphene	 as	 emerging	candidates	 in	neuroregeneration	and	neurodrug	delivery.	 Int	 J	Nanomedicine	10,	4267-4277.	Kanakia,	S.,	Toussaint,	J.D.,	Mullick	Chowdhury,	S.,	Tembulkar,	T.,	Lee,	S.,	Jiang,	Y.P.,	Lin,	 R.Z.,	 Shroyer,	 K.R.,	Moore,	W.,	 and	 Sitharaman,	 B.	 (2014).	Dose	 ranging,	expanded	 acute	 toxicity	 and	 safety	 pharmacology	 studies	 for	 intravenously	administered	functionalized	graphene	nanoparticle	formulations.	Biomaterials	35,	7022-7031.	Kang,	X.,	Wang,	J.,	Wu,	H.,	Liu,	J.,	Aksay,	I.A.,	and	Lin,	Y.	(2010).	A	graphene-based	electrochemical	sensor	for	sensitive	detection	of	paracetamol.	Talanta	81,	754-759.	Kästner,	J.	(2011).	Umbrella	sampling.	Adv.	Rev.	1.	Kim,	D.H.,	 Abidian,	M.,	 and	Martin,	D.C.	 (2004).	 Conducting	 polymers	 grown	 in	hydrogel	scaffolds	coated	on	neural	prosthetic	devices.	J	Biomed	Mater	Res	A	71,	577-585.	
	 33	
Kim,	 D.H.,	 and	 Martin,	 D.C.	 (2006).	 Sustained	 release	 of	 dexamethasone	 from	hydrophilic	 matrices	 using	 PLGA	 nanoparticles	 for	 neural	 drug	 delivery.	
Biomaterials	27,	3031-3037.	Kim,	H.,	Namgung,	R.,	Singha,	K.,	Oh,	I.K.,	and	Kim,	W.J.	(2011).	Graphene	oxide-polyethylenimine	nanoconstruct	as	a	gene	delivery	vector	and	bioimaging	tool.	
Bioconjug	Chem	22,	2558-2567.	Kim,	S.S.,	Kuang,	Z.,	Ngo,	Y.H.,	Farmer,	B.L.,	and	Naik,	R.R.	 (2015).	Biotic-Abiotic	Interactions:	Factors	 that	 Influence	Peptide-Graphene	 Interactions.	ACS	Appl	
Mater	Interfaces	7,	20447-20453.	Kostarelos,	K.,	Vincent,	M.,	Hebert,	C.,	 and	Garrido,	 J.A.	 (2017).	Graphene	 in	 the	Design	and	Engineering	of	Next-Generation	Neural	Interfaces.	Adv	Mater	29.	Kreuter,	 J.	 (2014).	 Drug	 delivery	 to	 the	 central	 nervous	 system	 by	 polymeric	nanoparticles:	what	do	we	know?	Adv	Drug	Deliv	Rev	71,	2-14.	Kreuter,	 J.,	 Ramge,	 P.,	 Petrov,	 V.,	 Hamm,	 S.,	 Gelperina,	 S.E.,	 Engelhardt,	 B.,	Alyautdin,	 R.,	 Von	 Briesen,	 H.,	 and	 Begley,	 D.J.	 (2003).	 Direct	 evidence	 that	polysorbate-80-coated	 poly(butylcyanoacrylate)	 nanoparticles	 deliver	 drugs	to	 the	 CNS	 via	 specific	 mechanisms	 requiring	 prior	 binding	 of	 drug	 to	 the	nanoparticles.	Pharm	Res	20,	409-416.	Kreuter,	J.,	Shamenkov,	D.,	Petrov,	V.,	Ramge,	P.,	Cychutek,	K.,	Koch-Brandt,	C.,	and	Alyautdin,	 R.	 (2002).	 Apolipoprotein-mediated	 transport	 of	 nanoparticle-bound	drugs	across	the	blood-brain	barrier.	J	Drug	Target	10,	317-325.	Kuo,	 Y.C.,	 and	 Chung,	 C.Y.	 (2012).	 Transcytosis	 of	 CRM197-grafted	polybutylcyanoacrylate	nanoparticles	for	delivering	zidovudine	across	human	brain-microvascular	endothelial	cells.	Colloids	Surf	B	Biointerfaces	91,	242-249.	Kuo,	Y.C.,	and	Liu,	Y.C.	 (2014).	Cardiolipin-incorporated	 liposomes	with	surface	CRM197	 for	 enhancing	 neuronal	 survival	 against	 neurotoxicity.	 Int	 J	 Pharm	473,	334-344.	Kurapati,	R.,	Backes,	C.,	Menard-Moyon,	C.,	Coleman,	J.N.,	and	Bianco,	A.	(2016).	White	Graphene	undergoes	Peroxidase	Degradation.	Angew	Chem	Int	Ed	Engl	55,	5506-5511.	Kuzum,	D.,	Takano,	H.,	Shim,	E.,	Reed,	 J.C.,	 Juul,	H.,	Richardson,	A.G.,	De	Vries,	 J.,	Bink,	H.,	Dichter,	M.A.,	Lucas,	T.H.,	Coulter,	D.A.,	Cubukcu,	E.,	and	Litt,	B.	(2014).	Transparent	 and	 flexible	 low	 noise	 graphene	 electrodes	 for	 simultaneous	electrophysiology	and	neuroimaging.	Nat	Commun	5,	5259.	Lerf,	 A.H.,	 H.;	 Forster,	 M.;	 Klinowski,	 J.	 (1998).	 Structure	 of	 Graphite	 Oxide	Revisited.	J.	Phys.	Chem.	B	102,	4477-4482.	Li,	N.,	Xiao,	T.,	Zhang,	Z.,	He,	R.,	Wen,	D.,	Cao,	Y.,	Zhang,	W.,	and	Chen,	Y.	(2015).	A	3D	graphene	oxide	microchip	and	a	Au-enwrapped	silica	nanocomposite-based	supersandwich	cytosensor	 toward	capture	and	analysis	of	 circulating	 tumor	cells.	Nanoscale	7,	16354-16360.	Li,	N.,	Zhang,	Q.,	Gao,	S.,	Song,	Q.,	Huang,	R.,	Wang,	L.,	Liu,	L.,	Dai,	J.,	Tang,	M.,	and	Cheng,	G.	(2013a).	Three-dimensional	graphene	foam	as	a	biocompatible	and	conductive	scaffold	for	neural	stem	cells.	Sci	Rep	3,	1604.	Li,	N.,	Zhang,	X.,	Song,	Q.,	Su,	R.,	Zhang,	Q.,	Kong,	T.,	Liu,	L.,	 Jin,	G.,	Tang,	M.,	and	Cheng,	G.	(2011).	The	promotion	of	neurite	sprouting	and	outgrowth	of	mouse	hippocampal	 cells	 in	 culture	by	graphene	 substrates.	Biomaterials	 32,	 9374-9382.	Li,	Y.,	Yuan,	H.,	Von	Dem	Bussche,	A.,	Creighton,	M.,	Hurt,	R.H.,	Kane,	A.B.,	and	Gao,	H.	(2013b).	Graphene	microsheets	enter	cells	through	spontaneous	membrane	
	 34	
penetration	at	edge	asperities	and	corner	sites.	Proc	Natl	Acad	Sci	U	S	A	110,	12295-12300.	Liao,	 K.H.,	 Lin,	 Y.S.,	 Macosko,	 C.W.,	 and	 Haynes,	 C.L.	 (2011).	 Cytotoxicity	 of	graphene	oxide	and	graphene	in	human	erythrocytes	and	skin	fibroblasts.	ACS	
Appl	Mater	Interfaces	3,	2607-2615.	Lim,	M.H.,	Jeung,	I.C.,	Jeong,	J.,	Yoon,	S.J.,	Lee,	S.H.,	Park,	J.,	Kang,	Y.S.,	Lee,	H.,	Park,	Y.J.,	Lee,	H.G.,	Lee,	S.J.,	Han,	B.S.,	Song,	N.W.,	Lee,	S.C.,	Kim,	J.S.,	Bae,	K.H.,	and	Min,	J.K.	(2016).	Graphene	oxide	induces	apoptotic	cell	death	in	endothelial	cells	by	activating	 autophagy	 via	 calcium-dependent	 phosphorylation	 of	 c-Jun	 N-terminal	kinases.	Acta	Biomater	46,	191-203.	Liu,	G.,	Shen,	H.,	Mao,	J.,	Zhang,	L.,	Jiang,	Z.,	Sun,	T.,	Lan,	Q.,	and	Zhang,	Z.	(2013a).	Transferrin	modified	graphene	oxide	for	glioma-targeted	drug	delivery:	in	vitro	and	in	vivo	evaluations.	ACS	Appl	Mater	Interfaces	5,	6909-6914.	Liu,	 J.,	 Cui,	 L.,	 and	 Losic,	 D.	 (2013b).	 Graphene	 and	 graphene	 oxide	 as	 new	nanocarriers	for	drug	delivery	applications.	Acta	Biomater	9,	9243-9257.	Liu,	L.,	Guo,	K.,	Lu,	J.,	Venkatraman,	S.S.,	Luo,	D.,	Ng,	K.C.,	Ling,	E.A.,	Moochhala,	S.,	and	 Yang,	 Y.Y.	 (2008a).	 Biologically	 active	 core/shell	 nanoparticles	 self-assembled	from	cholesterol-terminated	PEG-TAT	for	drug	delivery	across	the	blood-brain	barrier.	Biomaterials	29,	1509-1517.	Liu,	L.,	Venkatraman,	S.S.,	Yang,	Y.Y.,	Guo,	K.,	Lu,	J.,	He,	B.,	Moochhala,	S.,	and	Kan,	L.	 (2008b).	Polymeric	micelles	anchored	with	TAT	for	delivery	of	antibiotics	across	the	blood-brain	barrier.	Biopolymers	90,	617-623.	Liu,	T.C.,	Chuang,	M.C.,	Chu,	C.Y.,	Huang,	W.C.,	Lai,	H.Y.,	Wang,	C.T.,	Chu,	W.L.,	Chen,	S.Y.,	 and	 Chen,	 Y.Y.	 (2016).	 Implantable	 Graphene-based	 Neural	 Electrode	Interfaces	 for	 Electrophysiology	 and	 Neurochemistry	 in	 In	 Vivo	 Hyperacute	Stroke	Model.	ACS	Appl	Mater	Interfaces	8,	187-196.	Liu,	 X.,	 Ma,	 D.,	 Tang,	 H.,	 Tan,	 L.,	 Xie,	 Q.,	 Zhang,	 Y.,	 Ma,	 M.,	 and	 Yao,	 S.	 (2014).	Polyamidoamine	 dendrimer	 and	 oleic	 acid-functionalized	 graphene	 as	biocompatible	and	efficient	gene	delivery	vectors.	ACS	Appl	Mater	Interfaces	6,	8173-8183.	Liu,	Z.,	Robinson,	J.T.,	Sun,	X.,	and	Dai,	H.	(2008c).	PEGylated	nanographene	oxide	for	delivery	of	water-insoluble	cancer	drugs.	J	Am	Chem	Soc	130,	10876-10877.	Liu,	Z.R.,	T.J.;	Tabakman,	S.M.;	Yang,	K.;	Dai,	H.	(2011).	Carbon	materials	for	drug	delivery	&	cancer	therapy.	Mater.	Today	14,	316-323.	Lopez-Dolado,	E.,	Gonzalez-Mayorga,	A.,	Gutierrez,	M.C.,	and	Serrano,	M.C.	(2016).	Immunomodulatory	 and	 angiogenic	 responses	 induced	 by	 graphene	 oxide	scaffolds	in	chronic	spinal	hemisected	rats.	Biomaterials	99,	72-81.	Lopez-Dolado,	E.,	Gonzalez-Mayorga,	A.,	Portoles,	M.T.,	Feito,	M.J.,	Ferrer,	M.L.,	Del	Monte,	F.,	Gutierrez,	M.C.,	and	Serrano,	M.C.	(2015).	Subacute	Tissue	Response	to	3D	Graphene	Oxide	Scaffolds	Implanted	in	the	Injured	Rat	Spinal	Cord.	Adv	
Healthc	Mater	4,	1861-1868.	Loureiro,	J.A.,	Gomes,	B.,	Coelho,	M.A.,	Do	Carmo	Pereira,	M.,	and	Rocha,	S.	(2014).	Targeting	 nanoparticles	 across	 the	 blood-brain	 barrier	 with	 monoclonal	antibodies.	Nanomedicine	(Lond)	9,	709-722.	Lu,	J.,	Cheng,	C.,	He,	Y.S.,	Lyu,	C.,	Wang,	Y.,	Yu,	J.,	Qiu,	L.,	Zou,	D.,	and	Li,	D.	(2016).	Multilayered	Graphene	Hydrogel	Membranes	 for	Guided	Bone	Regeneration.	
Adv	Mater	28,	4025-4031.	Luan,	B.,	Huynh,	T.,	Zhao,	L.,	and	Zhou,	R.	(2015).	Potential	toxicity	of	graphene	to	cell	functions	via	disrupting	protein-protein	interactions.	ACS	Nano	9,	663-669.	
	 35	
Ma,	Q.,	Yang,	L.,	Jiang,	Z.,	Song,	Q.,	Xiao,	M.,	Zhang,	D.,	Ma,	X.,	Wen,	T.,	and	Cheng,	G.	(2016).	 Three-Dimensional	 Stiff	 Graphene	 Scaffold	 on	 Neural	 Stem	 Cells	Behavior.	ACS	Appl	Mater	Interfaces	8,	34227-34233.	Mahmoudifard,	 M.,	 Soleimani,	 M.,	 Hatamie,	 S.,	 Zamanlui,	 S.,	 Ranjbarvan,	 P.,	Vossoughi,	M.,	and	Hosseinzadeh,	S.	(2016).	The	different	fate	of	satellite	cells	on	conductive	composite	electrospun	nanofibers	with	graphene	and	graphene	oxide	nanosheets.	Biomed	Mater	11,	025006.	Mao,	 J.,	 Guo,	 R.,	 and	 Yan,	 L.T.	 (2014).	 Simulation	 and	 analysis	 of	 cellular	internalization	 pathways	 and	 membrane	 perturbation	 for	 graphene	nanosheets.	Biomaterials	35,	6069-6077.	Markovic,	 Z.M.,	 Harhaji-Trajkovic,	 L.M.,	 Todorovic-Markovic,	 B.M.,	 Kepic,	 D.P.,	Arsikin,	K.M.,	 Jovanovic,	 S.P.,	 Pantovic,	 A.C.,	 Dramicanin,	M.D.,	 and	Trajkovic,	V.S.	 (2011).	 In	 vitro	 comparison	 of	 the	 photothermal	 anticancer	 activity	 of	graphene	nanoparticles	and	carbon	nanotubes.	Biomaterials	32,	1121-1129.	Marrink,	S.J.,	Risselada,	H.J.,	Yefimov,	S.,	Tieleman,	D.P.,	and	De	Vries,	A.H.	(2007).	The	MARTINI	force	field:	coarse	grained	model	for	biomolecular	simulations.	J	
Phys	Chem	B	111,	7812-7824.	Martin,	C.,	Merino,	S.,	Gonzalez-Dominguez,	J.M.,	Rauti,	R.,	Ballerini,	L.,	Prato,	M.,	and	 Vazquez,	 E.	 (2017).	 Graphene	 Improves	 the	 Biocompatibility	 of	Polyacrylamide	Hydrogels:	 3D	Polymeric	 Scaffolds	 for	Neuronal	 Growth.	Sci	
Rep	7,	10942.	Mattei,	 T.A.,	 and	 Rehman,	 A.A.	 (2014).	 Technological	 developments	 and	 future	perspectives	on	graphene-based	metamaterials:	a	primer	 for	neurosurgeons.	
Neurosurgery	74,	499-516;	discussion	516.	Mccallion,	 C.,	 Burthem,	 J.,	 Rees-Unwin,	 K.,	 Golovanov,	 A.,	 and	 Pluen,	 A.	 (2016).	Graphene	 in	 therapeutics	 delivery:	 Problems,	 solutions	 and	 future	opportunities.	Eur	J	Pharm	Biopharm	104,	235-250.	Medina-Sanchez,	M.,	Miserere,	S.,	and	Merkoci,	A.	(2012).	Nanomaterials	and	lab-on-a-chip	technologies.	Lab	Chip	12,	1932-1943.	Menaa,	 F.,	 Abdelghani,	 A.,	 and	 Menaa,	 B.	 (2015).	 Graphene	 nanomaterials	 as	biocompatible	 and	 conductive	 scaffolds	 for	 stem	 cells:	 impact	 for	 tissue	engineering	and	regenerative	medicine.	J	Tissue	Eng	Regen	Med	9,	1321-1338.	Mendonca,	M.C.,	Soares,	E.S.,	De	Jesus,	M.B.,	Ceragioli,	H.J.,	Batista,	A.G.,	Nyul-Toth,	A.,	Molnar,	 J.,	Wilhelm,	 I.,	Marostica,	M.R.,	 Jr.,	Krizbai,	 I.,	and	Da	Cruz-Hofling,	M.A.	(2016a).	PEGylation	of	Reduced	Graphene	Oxide	Induces	Toxicity	in	Cells	of	the	Blood-Brain	Barrier:	An	in	Vitro	and	in	Vivo	Study.	Mol	Pharm	13,	3913-3924.	Mendonca,	M.C.,	Soares,	E.S.,	De	 Jesus,	M.B.,	Ceragioli,	H.J.,	 Irazusta,	S.P.,	Batista,	A.G.,	Vinolo,	M.A.,	Marostica	 Junior,	M.R.,	 and	Da	Cruz-Hofling,	M.A.	 (2016b).	Reduced	graphene	oxide:	nanotoxicological	profile	in	rats.	J	Nanobiotechnology	14,	53.	Meric,	 I.,	Han,	M.Y.,	Young,	A.F.,	Ozyilmaz,	B.,	Kim,	P.,	 and	Shepard,	K.L.	 (2008).	Current	 saturation	 in	 zero-bandgap,	 top-gated	 graphene	 field-effect	transistors.	Nat	Nanotechnol	3,	654-659.	Michaelis,	K.,	Hoffmann,	M.M.,	Dreis,	S.,	Herbert,	E.,	Alyautdin,	R.N.,	Michaelis,	M.,	Kreuter,	 J.,	 and	 Langer,	 K.	 (2006).	 Covalent	 linkage	 of	 apolipoprotein	 e	 to	albumin	 nanoparticles	 strongly	 enhances	 drug	 transport	 into	 the	 brain.	 J	
Pharmacol	Exp	Ther	317,	1246-1253.	
	 36	
Mittal,	 S.,	 Kumar,	 V.,	 Dhiman,	 N.,	 Chauhan,	 L.K.,	 Pasricha,	 R.,	 and	 Pandey,	 A.K.	(2016).	 Physico-chemical	 properties	 based	 differential	 toxicity	 of	 graphene	oxide/reduced	graphene	oxide	in	human	lung	cells	mediated	through	oxidative	stress.	Sci	Rep	6,	39548.	N.	V.	Apollo,	M.I.M.,	W.	Tong,	D.	A.	X.	Nayagam,	M.	N.	Shivdasani,	J.	Foroughi,	G.	G.	Wallace,	 S.	 Prawer,	 M.	 R.	 Ibbotson	 Adn	 D.	 J.	 Garrett	 (2015).	 Soft,	 Flexible	Freestanding	 Neural	 Stimulation	 and	 Recording	 Electrodes	 Fabricated	 from	Reduced	Graphene	Oxide.	Adv.	Funct.	Mater.	25,	3551-3559.	No,	Y.H.,	Kim,	N.H.,	Gnapareddy,	B.,	Choi,	B.,	Kim,	Y.T.,	Dugasani,	S.R.,	Lee,	O.S.,	Kim,	K.H.,	Ko,	Y.S.,	Lee,	S.,	Lee,	S.W.,	Park,	S.H.,	Eom,	K.,	and	Kim,	Y.H.	(2017).	Nature-Inspired	 Construction	 of	 Two-Dimensionally	 Self-Assembled	 Peptide	 on	Pristine	Graphene.	J	Phys	Chem	Lett	8,	3734-3739.	Novak,	T.G.,	Kim,	J.,	Song,	S.H.,	Jun,	G.H.,	Kim,	H.,	Jeong,	M.S.,	and	Jeon,	S.	(2016).	Fast	P3HT	Exciton	Dissociation	and	Absorption	Enhancement	of	Organic	Solar	Cells	by	PEG-Functionalized	Graphene	Quantum	Dots.	Small	12,	994-999.	Novoselov,	K.S.,	 Fal'ko,	V.I.,	 Colombo,	L.,	Gellert,	P.R.,	 Schwab,	M.G.,	 and	Kim,	K.	(2012).	A	roadmap	for	graphene.	Nature	490,	192-200.	Ou,	L.,	 Song,	B.,	 Liang,	H.,	 Liu,	 J.,	 Feng,	X.,	Deng,	B.,	 Sun,	T.,	 and	Shao,	L.	 (2016).	Toxicity	of	graphene-family	nanoparticles:	a	general	review	of	the	origins	and	mechanisms.	Part	Fibre	Toxicol	13,	57.	Ozboyaci,	M.,	Kokh,	D.B.,	Corni,	S.,	and	Wade,	R.C.	(2016).	Modeling	and	simulation	of	protein-surface	interactions:	achievements	and	challenges.	Q	Rev	Biophys	49,	e4.	P.	Kang,	M.C.W.,	S.	Nam	(2016).	Bioelectronics	with	two-dimensional	materials.	
Microelectron.	Eng.	161,	18-35.	Pandey,	P.K.,	Sharma,	A.K.,	and	Gupta,	U.	(2016).	Blood	brain	barrier:	An	overview	on	 strategies	 in	 drug	 delivery,	 realistic	 in	 vitro	 modeling	 and	 in	 vivo	 live	tracking.	Tissue	Barriers	4,	e1129476.	Pardridge,	W.M.	 (2001).	 BBB-Genomics:	 creating	 new	 openings	 for	 brain-drug	targeting.	Drug	Discov	Today	6,	381-383.	Pardridge,	W.M.	 (2007a).	Blood-brain	barrier	delivery	of	protein	and	non-viral	gene	 therapeutics	with	molecular	Trojan	horses.	 J	 Control	Release	 122,	 345-348.	Pardridge,	W.M.	(2007b).	Drug	targeting	to	the	brain.	Pharm	Res	24,	1733-1744.	Pardridge,	W.M.	 (2012).	Drug	 transport	 across	 the	 blood-brain	 barrier.	 J	 Cereb	
Blood	Flow	Metab	32,	1959-1972.	Park,	D.W.,	Ness,	 J.P.,	Brodnick,	S.K.,	Esquibel,	C.,	Novello,	 J.,	Atry,	F.,	Baek,	D.H.,	Kim,	H.,	Bong,	J.,	Swanson,	K.I.,	Suminski,	A.J.,	Otto,	K.J.,	Pashaie,	R.,	Williams,	J.C.,	and	 Ma,	 Z.	 (2018).	 Electrical	 Neural	 Stimulation	 and	 Simultaneous	 in	 Vivo	Monitoring	 with	 Transparent	 Graphene	 Electrode	 Arrays	 Implanted	 in	GCaMP6f	Mice.	ACS	Nano	12,	148-157.	Patra,	N.,	Song,	Y.,	and	Kral,	P.	(2011).	Self-assembly	of	graphene	nanostructures	on	nanotubes.	ACS	Nano	5,	1798-1804.	Patra,	N.,	Wang,	B.,	and	Kral,	P.	(2009).	Nanodroplet	activated	and	guided	folding	of	graphene	nanostructures.	Nano	Lett	9,	3766-3771.	Paul,	A.,	Hasan,	A.,	Kindi,	H.A.,	Gaharwar,	A.K.,	Rao,	V.T.,	Nikkhah,	M.,	 Shin,	 S.R.,	Krafft,	 D.,	 Dokmeci,	 M.R.,	 Shum-Tim,	 D.,	 and	 Khademhosseini,	 A.	 (2014).	Injectable	graphene	oxide/hydrogel-based	angiogenic	gene	delivery	system	for	vasculogenesis	and	cardiac	repair.	ACS	Nano	8,	8050-8062.	
	 37	
Pelin,	M.,	Fusco,	L.,	Leon,	V.,	Martin,	C.,	Criado,	A.,	Sosa,	S.,	Vazquez,	E.,	Tubaro,	A.,	and	Prato,	M.	(2017).	Differential	cytotoxic	effects	of	graphene	and	graphene	oxide	on	skin	keratinocytes.	Sci	Rep	7,	40572.	Perlmutter,	J.S.,	and	Mink,	J.W.	(2006).	Deep	brain	stimulation.	Annu	Rev	Neurosci	29,	229-257.	Petri,	B.,	Bootz,	A.,	Khalansky,	A.,	Hekmatara,	T.,	Muller,	R.,	Uhl,	R.,	Kreuter,	J.,	and	Gelperina,	S.	(2007).	Chemotherapy	of	brain	tumour	using	doxorubicin	bound	to	 surfactant-coated	 poly(butyl	 cyanoacrylate)	 nanoparticles:	 revisiting	 the	role	of	surfactants.	J	Control	Release	117,	51-58.	Phillips,	J.C.,	Braun,	R.,	Wang,	W.,	Gumbart,	J.,	Tajkhorshid,	E.,	Villa,	E.,	Chipot,	C.,	Skeel,	R.D.,	Kale,	L.,	and	Schulten,	K.	(2005).	Scalable	molecular	dynamics	with	NAMD.	J	Comput	Chem	26,	1781-1802.	Picaud,	 S.,	 and	Sahel,	 J.A.	 (2014).	Retinal	prostheses:	 clinical	 results	 and	 future	challenges.	C	R	Biol	337,	214-222.	Pumera,	M.	(2009).	Electrochemistry	of	graphene:	new	horizons	for	sensing	and	energy	storage.	Chem	Rec	9,	211-223.	Pykal,	M.,	Jurecka,	P.,	Karlicky,	F.,	and	Otyepka,	M.	(2016).	Modelling	of	graphene	functionalization.	Phys	Chem	Chem	Phys	18,	6351-6372.	Qian,	 J.,	Wang,	D.,	Cai,	F.H.,	Xi,	W.,	Peng,	L.,	Zhu,	Z.F.,	He,	H.,	Hu,	M.L.,	and	He,	S.	(2012).	Observation	of	multiphoton-induced	fluorescence	from	graphene	oxide	nanoparticles	and	applications	 in	in	vivo	 functional	bioimaging.	Angew	Chem	
Int	Ed	Engl	51,	10570-10575.	Qiu,	 H.,	 Sarathy,	 A.,	 Leburton,	 J.P.,	 and	 Schulten,	 K.	 (2015).	 Intrinsic	 Stepwise	Translocation	of	Stretched	ssDNA	in	Graphene	Nanopores.	Nano	Lett	15,	8322-8330.	Rafique,	 S.,	 Abdullah,	 S.M.,	 Shahid,	M.M.,	 Ansari,	M.O.,	 and	 Sulaiman,	 K.	 (2017).	Significantly	 improved	 photovoltaic	 performance	 in	 polymer	 bulk	heterojunction	solar	cells	with	graphene	oxide	/PEDOT:PSS	double	decked	hole	transport	layer.	Sci	Rep	7,	39555.	Raghnaill,	M.N.,	Bramini,	M.,	Ye,	D.,	Couraud,	P.O.,	Romero,	I.A.,	Weksler,	B.,	Aberg,	C.,	 Salvati,	 A.,	 Lynch,	 I.,	 and	 Dawson,	 K.A.	 (2014).	 Paracrine	 signalling	 of	inflammatory	 cytokines	 from	 an	 in	 vitro	 blood	 brain	 barrier	 model	 upon	exposure	to	polymeric	nanoparticles.	Analyst	139,	923-930.	Ragnaill,	M.N.,	Brown,	M.,	Ye,	D.,	Bramini,	M.,	Callanan,	S.,	Lynch,	I.,	and	Dawson,	K.A.	(2011).	Internal	benchmarking	of	a	human	blood-brain	barrier	cell	model	for	screening	of	nanoparticle	uptake	and	transcytosis.	Eur	J	Pharm	Biopharm	77,	360-367.	Rauti,	R.,	Lozano,	N.,	Leon,	V.,	Scaini,	D.,	Musto,	M.,	Rago,	 I.,	Ulloa	Severino,	F.P.,	Fabbro,	 A.,	 Casalis,	 L.,	 Vazquez,	 E.,	 Kostarelos,	 K.,	 Prato,	M.,	 and	 Ballerini,	 L.	(2016).	 Graphene	 Oxide	 Nanosheets	 Reshape	 Synaptic	 Function	 in	 Cultured	Brain	Networks.	ACS	Nano	10,	4459-4471.	Re,	 F.,	 Cambianica,	 I.,	 Zona,	 C.,	 Sesana,	 S.,	 Gregori,	 M.,	 Rigolio,	 R.,	 La	 Ferla,	 B.,	Nicotra,	F.,	Forloni,	G.,	Cagnotto,	A.,	Salmona,	M.,	Masserini,	M.,	and	Sancini,	G.	(2011).	Functionalization	of	liposomes	with	ApoE-derived	peptides	at	different	density	affects	cellular	uptake	and	drug	transport	across	a	blood-brain	barrier	model.	Nanomedicine	7,	551-559.	Reina,	G.,	Gonzalez-Dominguez,	J.M.,	Criado,	A.,	Vazquez,	E.,	Bianco,	A.,	and	Prato,	M.	 (2017).	 Promises,	 facts	 and	 challenges	 for	 graphene	 in	 biomedical	applications.	Chem	Soc	Rev	46,	4400-4416.	
	 38	
Ren,	C.,	Hu,	X.,	Li,	X.,	and	Zhou,	Q.	(2016).	Ultra-trace	graphene	oxide	in	a	water	environment	 triggers	 Parkinson's	 disease-like	 symptoms	 and	 metabolic	disturbance	in	zebrafish	larvae.	Biomaterials	93,	83-94.	Rip,	J.,	Schenk,	G.J.,	and	De	Boer,	A.G.	(2009).	Differential	receptor-mediated	drug	targeting	to	the	diseased	brain.	Expert	Opin	Drug	Deliv	6,	227-237.	Robinson,	J.T.,	Tabakman,	S.M.,	Liang,	Y.,	Wang,	H.,	Casalongue,	H.S.,	Vinh,	D.,	and	Dai,	 H.	 (2011).	 Ultrasmall	 reduced	 graphene	 oxide	 with	 high	 near-infrared	absorbance	for	photothermal	therapy.	J	Am	Chem	Soc	133,	6825-6831.	Rubin,	L.L.,	Barbu,	K.,	Bard,	F.,	Cannon,	C.,	Hall,	D.E.,	Horner,	H.,	Janatpour,	M.,	Liaw,	C.,	Manning,	K.,	Morales,	J.,	and	Et	Al.	(1991).	Differentiation	of	brain	endothelial	cells	in	cell	culture.	Ann	N	Y	Acad	Sci	633,	420-425.	Sahoo,	 S.,	 Bhattacharya,	 P.,	 Dhibar,	 S.,	 Hatui,	 G.,	 Das,	 T.,	 and	 Das,	 C.K.	 (2015).	Graphene/Poly(aniline-co-pyrrole)	 Nanocomposite:	 Potential	 Candidate	 for	Supercapacitor	and	Microwave	Absorbing	Applications.	J	Nanosci	Nanotechnol	15,	6931-6941.	Saraiva,	C.,	Praca,	C.,	Ferreira,	R.,	Santos,	T.,	Ferreira,	L.,	and	Bernardino,	L.	(2016).	Nanoparticle-mediated	brain	drug	delivery:	Overcoming	blood-brain	barrier	to	treat	neurodegenerative	diseases.	J	Control	Release	235,	34-47.	Sathe,	C.,	Girdhar,	A.,	Leburton,	J.P.,	and	Schulten,	K.	(2014).	Electronic	detection	of	 dsDNA	 transition	 from	 helical	 to	 zipper	 conformation	 using	 graphene	nanopores.	Nanotechnology	25,	445105.	Sathe,	 C.,	 Zou,	 X.,	 Leburton,	 J.P.,	 and	 Schulten,	 K.	 (2011).	 Computational	investigation	of	DNA	detection	using	graphene	nanopores.	ACS	Nano	5,	8842-8851.	Sayyar,	 S.,	 Bjorninen,	 M.,	 Haimi,	 S.,	 Miettinen,	 S.,	 Gilmore,	 K.,	 Grijpma,	 D.,	 and	Wallace,	 G.	 (2016).	 UV	 Cross-Linkable	 Graphene/Poly(trimethylene	Carbonate)	Composites	for	3D	Printing	of	Electrically	Conductive	Scaffolds.	ACS	
Appl	Mater	Interfaces	8,	31916-31925.	Seabra,	A.B.,	Paula,	A.J.,	De	Lima,	R.,	Alves,	O.L.,	and	Duran,	N.	(2014).	Nanotoxicity	of	graphene	and	graphene	oxide.	Chem	Res	Toxicol	27,	159-168.	Semmler-Behnke,	M.,	Kreyling,	W.G.,	Lipka,	J.,	Fertsch,	S.,	Wenk,	A.,	Takenaka,	S.,	Schmid,	G.,	 and	Brandau,	W.	 (2008).	 Biodistribution	 of	 1.4-	 and	 18-nm	gold	particles	in	rats.	Small	4,	2108-2111.	Serrano,	M.C.,	 Patiño,	 J.,	 García-Rama,	 C.,	 Ferrer,	M.L.,	 Fierro,	 J.L.G.,	 Tamayo,	 A.,	Collazos-Castro,	J.E.,	Del	Monte,	F.,	and	Gutiérrez,	M.C.	(2014).	3D	free-standing	porous	scaffolds	made	of	graphene	oxide	as	substrates	for	neural	cell	growth.	J.	
Mater.	Chem.	B	2,	5698-5706.	Servant,	A.,	Bianco,	A.,	Prato,	M.,	and	Kostarelos,	K.	(2014a).	Graphene	for	multi-functional	 synthetic	biology:	 the	 last	 'zeitgeist'	 in	nanomedicine.	Bioorg	Med	
Chem	Lett	24,	1638-1649.	Servant,	A.,	Leon,	V.,	Jasim,	D.,	Methven,	L.,	Limousin,	P.,	Fernandez-Pacheco,	E.V.,	Prato,	 M.,	 and	 Kostarelos,	 K.	 (2014b).	 Graphene-based	 electroresponsive	scaffolds	 as	 polymeric	 implants	 for	 on-demand	 drug	 delivery.	 Adv	 Healthc	
Mater	3,	1334-1343.	Song,	 Q.,	 Jiang,	 Z.,	 Li,	 N.,	 Liu,	 P.,	 Liu,	 L.,	 Tang,	 M.,	 and	 Cheng,	 G.	 (2014).	 Anti-inflammatory	 effects	 of	 three-dimensional	 graphene	 foams	 cultured	 with	microglial	cells.	Biomaterials	35,	6930-6940.	Spelman,	F.A.	(2006).	Cochlear	electrode	arrays:	past,	present	and	future.	Audiol	
Neurootol	11,	77-85.	
	 39	
Strazielle,	N.,	and	Ghersi-Egea,	J.F.	(2013).	Physiology	of	blood-brain	interfaces	in	relation	 to	 brain	 disposition	 of	 small	 compounds	 and	macromolecules.	Mol	
Pharm	10,	1473-1491.	Sun,	X.,	Feng,	Z.,	Hou,	T.,	and	Li,	Y.	 (2014).	Mechanism	of	graphene	oxide	as	an	enzyme	 inhibitor	 from	 molecular	 dynamics	 simulations.	 ACS	 Appl	 Mater	
Interfaces	6,	7153-7163.	Sun,	X.,	Liu,	Z.,	Welsher,	K.,	Robinson,	J.T.,	Goodwin,	A.,	Zaric,	S.,	and	Dai,	H.	(2008).	Nano-Graphene	Oxide	for	Cellular	Imaging	and	Drug	Delivery.	Nano	Res	1,	203-212.	Tabatabaei,	S.N.,	Girouard,	H.,	Carret,	A.S.,	and	Martel,	S.	(2015).	Remote	control	of	the	 permeability	 of	 the	 blood-brain	 barrier	 by	 magnetic	 heating	 of	nanoparticles:	A	proof	of	concept	for	brain	drug	delivery.	J	Control	Release	206,	49-57.	Thompson,	B.C.,	Murray,	E.,	and	Wallace,	G.G.	(2015).	Graphite	Oxide	to	Graphene.	Biomaterials	to	Bionics.	Adv	Mater	27,	7563-7582.	Tian,	X.,	Yang,	Z.,	Duan,	G.,	Wu,	A.,	Gu,	Z.,	Zhang,	L.,	Chen,	C.,	Chai,	Z.,	Ge,	C.,	and	Zhou,	R.	(2017).	Graphene	Oxide	Nanosheets	Retard	Cellular	Migration	via	Disruption	of	Actin	Cytoskeleton.	Small	13.	Titov,	 A.V.,	 Kral,	 P.,	 and	 Pearson,	 R.	 (2010).	 Sandwiched	 graphene--membrane	superstructures.	ACS	Nano	4,	229-234.	Tonelli,	F.M.,	Goulart,	V.A.,	Gomes,	K.N.,	Ladeira,	M.S.,	Santos,	A.K.,	Lorencon,	E.,	Ladeira,	 L.O.,	 and	 Resende,	 R.R.	 (2015).	 Graphene-based	 nanomaterials:	biological	 and	 medical	 applications	 and	 toxicity.	 Nanomedicine	 (Lond)	 10,	2423-2450.	Tosi,	G.,	Costantino,	L.,	Ruozi,	B.,	Forni,	F.,	 and	Vandelli,	M.A.	(2008).	Polymeric	nanoparticles	for	the	drug	delivery	to	the	central	nervous	system.	Expert	Opin	
Drug	Deliv	5,	155-174.	Treat,	L.H.,	Mcdannold,	N.,	Vykhodtseva,	N.,	Zhang,	Y.,	Tam,	K.,	and	Hynynen,	K.	(2007).	Targeted	delivery	of	doxorubicin	to	the	rat	brain	at	therapeutic	levels	using	MRI-guided	focused	ultrasound.	Int	J	Cancer	121,	901-907.	Tu,	Q.,	Pang,	L.,	Chen,	Y.,	Zhang,	Y.,	Zhang,	R.,	Lu,	B.,	and	Wang,	J.	(2014).	Effects	of	surface	 charges	 of	 graphene	 oxide	 on	 neuronal	 outgrowth	 and	 branching.	
Analyst	139,	105-115.	Tu,	Y.,	Lv,	M.,	Xiu,	P.,	Huynh,	T.,	Zhang,	M.,	Castelli,	M.,	Liu,	Z.,	Huang,	Q.,	Fan,	C.,	Fang,	 H.,	 and	 Zhou,	 R.	 (2013).	 Destructive	 extraction	 of	 phospholipids	 from	Escherichia	coli	membranes	by	graphene	nanosheets.	Nat	Nanotechnol	8,	594-601.	Ulbrich,	 K.,	 Hekmatara,	 T.,	 Herbert,	 E.,	 and	Kreuter,	 J.	 (2009).	 Transferrin-	 and	transferrin-receptor-antibody-modified	 nanoparticles	 enable	 drug	 delivery	across	the	blood-brain	barrier	(BBB).	Eur	J	Pharm	Biopharm	71,	251-256.	Ulbrich,	K.,	Knobloch,	T.,	 and	Kreuter,	 J.	 (2011).	Targeting	 the	 insulin	 receptor:	nanoparticles	 for	drug	delivery	across	 the	blood-brain	barrier	 (BBB).	 J	Drug	
Target	19,	125-132.	Ulloa	Severino,	F.P.,	Ban,	J.,	Song,	Q.,	Tang,	M.,	Bianconi,	G.,	Cheng,	G.,	and	Torre,	V.	(2016).	The	role	of	dimensionality	 in	neuronal	network	dynamics.	Sci	Rep	6,	29640.	Upadhyay,	R.K.	(2014).	Drug	delivery	systems,	CNS	protection,	and	the	blood	brain	barrier.	Biomed	Res	Int	2014,	869269.	
	 40	
Van	 Rooy,	 I.,	 Mastrobattista,	 E.,	 Storm,	 G.,	 Hennink,	W.E.,	 and	 Schiffelers,	 R.M.	(2011).	Comparison	of	five	different	targeting	ligands	to	enhance	accumulation	of	liposomes	into	the	brain.	J	Control	Release	150,	30-36.	Veliev,	F.,	Han,	Z.,	Kalita,	D.,	Briancon-Marjollet,	A.,	Bouchiat,	V.,	and	Delacour,	C.	(2017).	 Recording	 Spikes	 Activity	 in	 Cultured	 Hippocampal	 Neurons	 Using	Flexible	or	Transparent	Graphene	Transistors.	Front	Neurosci	11,	466.	Wagner,	S.,	Zensi,	A.,	Wien,	S.L.,	Tschickardt,	S.E.,	Maier,	W.,	Vogel,	T.,	Worek,	F.,	Pietrzik,	 C.U.,	 Kreuter,	 J.,	 and	 Von	 Briesen,	 H.	 (2012).	 Uptake	mechanism	 of	ApoE-modified	nanoparticles	on	brain	 capillary	endothelial	 cells	 as	a	blood-brain	barrier	model.	PLoS	One	7,	e32568.	Wang,	D.C.,	Zhang,	Y.,	Chen,	H.Y.,	Li,	X.L.,	Qin,	L.J.,	Li,	Y.J.,	Zhang,	H.Y.,	and	Wang,	S.	(2012).	Hyperthermia	promotes	apoptosis	and	suppresses	invasion	in	C6	rat	glioma	cells.	Asian	Pac	J	Cancer	Prev	13,	3239-3245.	Wang,	X.,	Sun,	X.,	Lao,	J.,	He,	H.,	Cheng,	T.,	Wang,	M.,	Wang,	S.,	and	Huang,	F.	(2014).	Multifunctional	 graphene	 quantum	 dots	 for	 simultaneous	 targeted	 cellular	imaging	and	drug	delivery.	Colloids	Surf	B	Biointerfaces	122,	638-644.	Wang,	Y.,	Li,	Z.,	Hu,	D.,	Lin,	C.T.,	Li,	J.,	and	Lin,	Y.	(2010).	Aptamer/graphene	oxide	nanocomplex	for	in	situ	molecular	probing	in	living	cells.	J	Am	Chem	Soc	132,	9274-9276.	Wells,	D.B.,	Belkin,	M.,	Comer,	J.,	and	Aksimentiev,	A.	(2012).	Assessing	graphene	nanopores	for	sequencing	DNA.	Nano	Lett	12,	4117-4123.	Wick,	P.,	Louw-Gaume,	A.E.,	Kucki,	M.,	Krug,	H.F.,	Kostarelos,	K.,	Fadeel,	B.,	Dawson,	K.A.,	Salvati,	A.,	Vazquez,	E.,	Ballerini,	L.,	Tretiach,	M.,	Benfenati,	F.,	Flahaut,	E.,	Gauthier,	 L.,	 Prato,	 M.,	 and	 Bianco,	 A.	 (2014).	 Classification	 framework	 for	graphene-based	materials.	Angew	Chem	Int	Ed	Engl	53,	7714-7718.	Willems,	 N.,	 Urtizberea,	 A.,	 Verre,	 A.F.,	 Iliut,	 M.,	 Lelimousin,	 M.,	 Hirtz,	 M.,	Vijayaraghavan,	 A.,	 and	 Sansom,	 M.S.	 (2017).	 Biomimetic	 Phospholipid	Membrane	 Organization	 on	 Graphene	 and	 Graphene	 Oxide	 Surfaces:	 A	Molecular	Dynamics	Simulation	Study.	ACS	Nano	11,	1613-1625.	Wolburg,	H.,	and	Lippoldt,	A.	(2002).	Tight	junctions	of	the	blood-brain	barrier:	development,	composition	and	regulation.	Vascul	Pharmacol	38,	323-337.	X.	 Zhang,	 J.Y.,	 C.	 Peng,	 W.	 Hu,	 Z.	 Zhu,	 W.	 Li,	 Et	 Al.	 (2011).	 Distribution	 and	biocompatibility	 studies	 of	 graphene	 oxide	 in	 mice	 after	 intravenous	administration.	Carbon	49,	986-995.	Xiao,	S.,	Zhou,	D.,	Luan,	P.,	Gu,	B.,	Feng,	L.,	Fan,	S.,	Liao,	W.,	Fang,	W.,	Yang,	L.,	Tao,	E.,	 Guo,	 R.,	 and	 Liu,	 J.	 (2016).	 Graphene	 quantum	 dots	 conjugated	neuroprotective	 peptide	 improve	 learning	 and	 memory	 capability.	
Biomaterials	106,	98-110.	Xu,	X.,	Wang,	J.,	Wang,	Y.,	Zhao,	L.,	Li,	Y.,	and	Liu,	C.	(2017).	Formation	of	graphene	oxide-hybridized	nanogels	for	combinative	anticancer	therapy.	Nanomedicine.	Yang,	H.W.,	Huang,	C.Y.,	Lin,	C.W.,	Liu,	H.L.,	Huang,	C.W.,	Liao,	S.S.,	Chen,	P.Y.,	Lu,	Y.J.,	Wei,	 K.C.,	 and	Ma,	 C.C.	 (2014).	 Gadolinium-functionalized	 nanographene	oxide	 for	 combined	 drug	 and	 microRNA	 delivery	 and	 magnetic	 resonance	imaging.	Biomaterials	35,	6534-6542.	Yang,	 K.,	 Hu,	 L.,	Ma,	 X.,	 Ye,	 S.,	 Cheng,	 L.,	 Shi,	X.,	 Li,	 C.,	 Li,	 Y.,	 and	 Liu,	 Z.	 (2012).	Multimodal	 imaging	 guided	 photothermal	 therapy	 using	 functionalized	graphene	 nanosheets	 anchored	 with	magnetic	 nanoparticles.	 Adv	 Mater	 24,	1868-1872.	
	 41	
Yang,	K.,	Zhang,	S.,	Zhang,	G.,	Sun,	X.,	Lee,	S.T.,	and	Liu,	Z.	(2010).	Graphene	in	mice:	ultrahigh	in	vivo	tumor	uptake	and	efficient	photothermal	therapy.	Nano	Lett	10,	3318-3323.	Yang,	K.F.,	L.;	Shi,	X.;	Liu,	Z.	(2013).	Nano-Graphene	in	Biomedicine:	Theranostic	Application.	Chem.	Soc.	Rev.	42,	530-547.	Yang,	L.,	Wang,	F.,	Han,	H.,	Yang,	L.,	Zhang,	G.,	and	Fan,	Z.	(2015a).	Functionalized	graphene	 oxide	 as	 a	 drug	 carrier	 for	 loading	 pirfenidone	 in	 treatment	 of	subarachnoid	hemorrhage.	Colloids	Surf	B	Biointerfaces	129,	21-29.	Yang,	W.,	 Zhao,	 Y.,	 He,	 X.,	 Chen,	 Y.,	 Xu,	 J.,	 Li,	 S.,	 Yang,	 Y.,	 and	 Jiang,	 Y.	 (2015b).	Flexible	 conducting	 polymer/reduced	 graphene	 oxide	 films:	 synthesis,	characterization,	and	electrochemical	performance.	Nanoscale	Res	Lett	10,	222.	Ye,	J.,	Li,	X.,	Zhao,	J.,	Mei,	X.	And	Li,	Q.	(2016).	Efficient	and	stable	perovskite	solar	cells	based	on	functional	graphene-modified	P3HT	holetransporting	layer.	RCS	
Adv	6,	36356.	Zeng,	S.,	Zhou,	G.,	Guo,	J.,	Zhou,	F.,	and	Chen,	 J.	 (2016).	Molecular	simulations	of	conformation	change	and	aggregation	of	HIV-1	Vpr13-33	on	graphene	oxide.	
Sci	Rep	6,	24906.	Zensi,	A.,	Begley,	D.,	Pontikis,	C.,	Legros,	C.,	Mihoreanu,	L.,	Buchel,	C.,	and	Kreuter,	J.	(2010).	Human	serum	albumin	nanoparticles	modified	with	apolipoprotein	A-I	cross	the	blood-brain	barrier	and	enter	the	rodent	brain.	J	Drug	Target	18,	842-848.	Zensi,	A.,	Begley,	D.,	Pontikis,	C.,	Legros,	C.,	Mihoreanu,	L.,	Wagner,	S.,	Buchel,	C.,	Von	Briesen,	H.,	and	Kreuter,	 J.	 (2009).	Albumin	nanoparticles	 targeted	with	Apo	E	enter	the	CNS	by	transcytosis	and	are	delivered	to	neurones.	J	Control	
Release	137,	78-86.	Zhang,	D.,	Zhang,	Z.,	Liu,	Y.,	Chu,	M.,	Yang,	C.,	Li,	W.,	Shao,	Y.,	Yue,	Y.,	and	Xu,	R.	(2015).	 The	 short-	 and	 long-term	 effects	 of	 orally	 administered	 high-dose	reduced	graphene	oxide	nanosheets	on	mouse	behaviors.	Biomaterials	68,	100-113.	Zhang,	H.G.,	G.;	Zhao,	Y.	(2013).	Recent	advancements	of	graphene	in	bomedicine.	
Journal	of	Materials	Chemistry	B	1,	2542-2567.	Zhang,	 L.,	 Lu,	 Z.,	 Zhao,	 Q.,	 Huang,	 J.,	 Shen,	 H.,	 and	 Zhang,	 Z.	 (2011).	 Enhanced	chemotherapy	efficacy	by	 sequential	delivery	of	 siRNA	and	anticancer	drugs	using	PEI-grafted	graphene	oxide.	Small	7,	460-464.	Zhang,	Q.,	Wu,	Z.,	Li,	N.,	Pu,	Y.,	Wang,	B.,	Zhang,	T.,	and	Tao,	J.	(2017).	Advanced	review	of	graphene-based	nanomaterials	in	drug	delivery	systems:	Synthesis,	modification,	toxicity	and	application.	Mater	Sci	Eng	C	Mater	Biol	Appl	77,	1363-1375.	Zhao,	 X.,	 Shang,	 T.,	 Zhang,	 X.,	 Ye,	 T.,	Wang,	 D.,	 and	 Rei,	 L.	 (2016a).	 Passage	 of	Magnetic	 Tat-Conjugated	 Fe3O4@SiO2	Nanoparticles	Across	 In	Vitro	Blood-Brain	Barrier.	Nanoscale	Res	Lett	11,	451.	Zhao,	Y.,	Gong,	J.,	Niu,	C.,	Wei,	Z.,	Shi,	J.,	Li,	G.,	Yang,	Y.,	and	Wang,	H.	(2017).	A	new	electrospun	 graphene-silk	 fibroin	 composite	 scaffolds	 for	 guiding	 Schwann	cells.	J	Biomater	Sci	Polym	Ed	28,	2171-2185.	Zhao,	Y.,	Li,	Z.,	Sharma,	U.K.,	Sharma,	N.,	Song,	G.,	and	Van	Der	Eycken,	E.V.	(2016b).	Copper-catalyzed	alkylarylation	of	activated	alkenes	using	isocyanides	as	the	alkyl	 source:	 an	 efficient	 radical	 access	 to	 3,3-dialkylated	 oxindoles.	 Chem	
Commun	(Camb)	52,	6395-6398.	
	 42	
Zhou,	 H.,	 Zhao,	 K.,	 Li,	 W.,	 Yang,	 N.,	 Liu,	 Y.,	 Chen,	 C.,	 and	 Wei,	 T.	 (2012).	 The	interactions	between	pristine	graphene	and	macrophages	and	the	production	of	cytokines/chemokines	via	TLR-	and	NF-kappaB-related	signaling	pathways.	
Biomaterials	33,	6933-6942.	Zhou,	K.,	Motamed,	S.,	Thouas,	G.A.,	Bernard,	C.C.,	Li,	D.,	Parkington,	H.C.,	Coleman,	H.A.,	 Finkelstein,	 D.I.,	 and	 Forsythe,	 J.S.	 (2016).	 Graphene	 Functionalized	Scaffolds	 Reduce	 the	 Inflammatory	 Response	 and	 Supports	 Endogenous	Neuroblast	 Migration	 when	 Implanted	 in	 the	 Adult	 Brain.	 PLoS	 One	 11,	e0151589.	Zhu,	 C.,	 Han,	 T.Y.,	 Duoss,	 E.B.,	 Golobic,	 A.M.,	 Kuntz,	 J.D.,	 Spadaccini,	 C.M.,	 and	Worsley,	 M.A.	 (2015).	 Highly	 compressible	 3D	 periodic	 graphene	 aerogel	microlattices.	Nat	Commun	6,	6962.	Zuccaro,	L.,	Tesauro,	C.,	Kurkina,	T.,	Fiorani,	P.,	Yu,	H.K.,	Knudsen,	B.R.,	Kern,	K.,	Desideri,	 A.,	 and	 Balasubramanian,	 K.	 (2015).	 Real-Time	 Label-Free	 Direct	Electronic	 Monitoring	 of	 Topoisomerase	 Enzyme	 Binding	 Kinetics	 on	Graphene.	ACS	Nano	9,	11166-11176.	Zuo,	G.Z.,	X.;	Huang,	Q.;	Fang,	H.;	Zhou,	R.	(2011).	Adsorption	of	Villin	Headpiece	onto	 Graphene,	 Carbon	 Nanotube,	 and	 C60:	 Effect	 of	 Conctacting	 Surface	Curvatures	on	Binding	Affinity.	J.	Phys.	Chem.	C	115,	23323-23328.	
 
